{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["汇总"],"not_rendered":{"external_links":1,"defined_names":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"汇总","index":0,"n_rows":213,"n_cols":14,"rows_kept":213,"merged":[[0,0,0,13],[1,0,1,13],[2,0,3,0],[2,1,2,3],[2,4,2,10],[2,11,2,13],[212,0,212,13]],"flags":["formulas_cached_only"]}
["超药品说明书用药目录（2019年版）"]
["（广东省药学会2019年6月17日发布）"]
["排序","药品信息",null,null,"超说明书内容",{"$nulls":6},"micromedex 分级"]
[null,"通用名","剂型","规格","适应证","剂量","人群","径途","其他","具体用法","依据以及参考文献","有效性","推荐等级","证据强度"]
[1,"A型肉毒毒素","粉针","100IU","上肢肢体痉挛",{"$nulls":4},"参见FDA说明书","美国FDA已批准A型肉毒毒素用于治疗上肢肢体痉挛","Class Ⅱa"," Class IIa"," Category B"]
[2,"A型肉毒毒素","粉针","100IU","下肢肢体痉挛",{"$nulls":4},"参见FDA说明书","美国FDA已批准A型肉毒毒素用于治疗下肢肢体痉挛","Class Ⅱa","Class Ⅱa","Category B"]
[3,"A型肉毒毒素","粉针","100IU","斜颈症",{"$nulls":4},"参见FDA说明书","美国FDA已批准A型肉毒毒素用于治疗斜颈症","Class I","Class Ⅱa","Category B"]
[4,"A型肉毒毒素","粉针","100IU","原发性腋下多汗症（重度）",{"$nulls":4},"每腋下注射50IU","美国FDA已批准A型肉毒毒素用于治疗原发性腋下多汗症（重度）","Class I","Class Ⅱa","Category B"]
[5,"A型肉毒毒素","粉针","100IU","减轻皱纹",{"$nulls":4},"常用的单点注射剂量为1-4U[2]","1.美国FDA已批准A型肉毒毒素用于减轻皱纹        \n2.中华医学会整形外科学分会微创美容专业学组《A型肉毒毒素在整形外科的临床应用指南》     ","ClassⅡa","Class Ⅱb","Category B"]
[6,"阿立哌唑","片剂","5mg","孤独症相关的易激惹症状"," ","6-17岁儿童青少年",null,null,"起始剂量2mg/d，逐渐增加至5 mg/d，间隔至少1周增加5 mg/d，至10 - 15 mg/d","美国FDA已批准用于治疗6-17岁儿童/青少年的孤独症-精神运动易激惹型","Class Ⅱa","Class Ⅱb","Category B"]
[7,"阿立哌唑","片剂","5mg","与碳酸锂或丙戊酸钠合并使用，双相障碍Ⅰ型治疗辅助用药"," ","成人",null,null,"10-15 mg/d,根据反应可增加到30mg/d，但＞30mg/d安全性尚未进行评价","美国FDA已批准作为成人双相障碍Ⅰ型治疗辅助用药","Class Ⅱa","Class Ⅱb","Category B"]
[8,"阿立哌唑","片剂","5mg","双相障碍Ⅰ型躁狂或混合状态"," ","10-17岁儿童青少年",null,null,"2 mg/d 维持2d,两天内加量至5 mg/d, 继续增加剂量至10 mg/d，根据病情可每天增加5mg","美国FDA已批准用于治疗10-17岁儿童/青少年双相障碍Ⅰ型躁狂或混合状态","Class Ⅱa","Class Ⅱb","Category B"]
[9,"阿立哌唑","片剂","5mg","抽动秽语综合征"," ","6-18岁儿童青少年",null,null,"体重小于50kg的用药量：2 mg/d 维持2d,增加至5mg/d,最大剂量增至10mg/d，但间隔至少一周；\n体重大于50kg的用药量：2 mg/d 维持2d,增加至5mg/d维持5d,第八天剂量增至10mg/d，最大剂量为20mg/d，但间隔至少一周。","美国FDA已批准用于治疗6-18岁儿童/青少年的抽动秽语综合征","Class Ⅱa","Class Ⅱb","Category B"]
[10,"阿立哌唑","片剂","5mg","重症抑郁辅助用药"," ","成人",null,null,"起始剂量2-5 mg/d，推荐剂量 2-15 mg/d","美国FDA已批准作为重症抑郁辅助用药","Class Ⅱa","Class Ⅱb","Category B"]
[11,"阿立哌唑","片剂","5mg","精神分裂症"," ","13-17岁儿童青少年",null,null,"起始剂量2mg/d，两天后增加至5 mg/d，第五天增加至10mg/d，维持剂量10mg/d，最大剂量30mg/d.","美国FDA已批准用于治疗13-17岁儿童/青少年的精神分裂症","Class Ⅱa","Class Ⅱb","Category B"]
[12,"阿司匹林","肠溶片","100mg ","预防子痫前期",{"$nulls":4},"对存在子痫前期复发风险和子痫前期高危因素者，在妊娠早中期（妊娠12～16周）开始服用小剂量阿司匹林（50-100mg），可维持到孕28周。","1..美国FDA未批准阿司匹林用于预防子痫前期\n2. 中华医学会妇产科学会《妊娠期高血压疾病诊治指南（2015）》  \n3.美国妇产科医师学会ACOG《妊娠期高血压诊断和管理指南》 \n4.美国预防服务工作组USPSTF《低剂量阿司匹林预防子痫前期临床指南》","Class I","Class Ⅱa","Category A"]
[13,"埃索美拉唑","注射液","40mg","内镜下用于胃损伤止血、术后复发性消化道出血预防（高危患者）",{"$nulls":4},"胃镜检查后立即给予负荷剂量80mg iv，续以8mg/h iv 维持3～6天","1.美国FDA提及可用于降低成人治疗性内窥镜检查后胃或十二指肠溃疡再出血的风险\n2.中华医学会内科学会《急性非静脉曲张性上消化道出血诊治指南（2015）》 ","Class Ⅱb","Class Ⅱb","Category B"]
[14,"艾司西酞普兰","片剂","10mg","抑郁症（重度）",null,"12岁-17岁青少年",null,null,"起始剂量为10mg/d，维持剂量10mg/d，3周后可增至20mg/d","1.美国已FDA批准艾司西酞普兰用于12岁至17岁青少年重度抑郁症的治疗                                                     2.中华医学会精神病学会《抑郁障碍防治指南》","Class Ⅱb","Class Ⅱb","Category B"]
[15,"艾司西酞普兰","片剂","①5mg                \n②10mg","焦虑症",null,"成人",null,null,"10mg/d，一周后可加至20mg/d","美国FDA已批准艾司西酞普兰治疗成人广泛性焦虑障碍","Class Ⅰ","Class Ⅱa","Category B"]
[16,"艾司西酞普兰","片剂","①5mg              \n②20mg ","强迫症",null,"成人",null,null,"初始剂量及滴定:口服10mg /d。1周后可增加至20mg/d","1.美国FDA未批准用于艾司西酞普兰用于强迫症                              \n2.美国APA精神病学学会《Practice guideline for the  Treatment of Patients With Obsessive～Compulsive Disorder》 ","Class Ⅱa","Class Ⅱb","Category B"]
[17,"奥氮平","片剂","5mg","精神分裂症",null,"13-17岁青少年",null,null,"起始剂量为2.5-5mg/d，以2.5-5mg幅度增减，目标剂量为10mg/d，最大剂量为20mg/d","1.美国FDA已批准奥氮平口服剂型用于治疗13-17岁儿童精神分裂症                             \n2.中华医学会精神医学会2015《精神分裂症防治指南》","Class IIa","Class Ⅱb","Category B"]
[18,"奥氮平","片剂","5mg","化疗相关呕吐",{"$nulls":4},"①10mg/次，d1-4（高致吐方案）\n②10mg/次，d1-3（中致吐方案）","1.美国FDA未批准奥氮平用于化疗相关的呕吐\n2.NCCN临床实践指南：止呕（2018.V3）\n3.中国抗癌协会癌症康复与姑息治疗专业委员会、中国临床肿瘤学会抗肿瘤药物安全管理专家委员会《肿瘤治疗相关呕吐防治指南( 2014 版)》","Class Ⅱa","Class Ⅱb","Category B"]
[19,"奥氮平","片剂","5mg","抑郁症",{"$nulls":4},"与氟西汀联合治疗重症抑郁症时起始剂量5mg qn，可调整至5-20mg qn；","美国FDA已批准奥氮平口服剂型与氟西汀联合用于治疗成人双相I型抑郁症、重度抑郁症               ","Class Ⅱa","Class Ⅱb","Category B"]
[20,"奥曲肽","注射液","0.1mg/支","肠梗阻",{"$nulls":4},"皮下注射，每日三次，每次0.1-0.3mg，直至症状缓解","1.醋酸奥曲肽注射液善宁日本版说明书批准该用法\n2.NCCN Clinical Practice Guidelines in Oncology（NCCN Guidelines）Palliative care\n3.Role of octrotide in the management of patients with cancer\n4.晚期癌症患者合并肠梗阻治疗的专家共识","ClassⅡb","ClassⅡb","Category B"]
[21,"奥沙利铂","粉针","50mg","结肠癌，辅助性II期，与5-氟尿嘧啶/亚叶酸组合",{"$nulls":4},"85mg/m2","1.美国FDA未批准奥沙利铂用于与5-氟尿嘧啶/亚叶酸联合辅助治疗成人II期结肠癌\n2.NCCN临床实践指南：结直肠癌筛查（2018.V1）","Class Ⅱa","Class Ⅱb","Category B"]
[22,"奥沙利铂","粉针","50mg","食管癌、胃癌、结直肠癌的辅助化疗，胆道恶性肿瘤及淋巴瘤的二线治疗",{"$nulls":4},"85~130mg/m2。详见NCCN指南","1.FDA已批准奥沙利铂用于 III期结肠癌的辅助治疗\n2.NCCN临床实践指南：胃癌（2019.V1）                                  \n3.NCCN临床实践指南：食道癌和胃食管交界处癌（2019.V1）                                     \n4.NCCN临床实践指南：肝胆肿瘤（2019.V2）\n5.NCCN临床实践指南：直肠癌（2019.V2）","食管癌：\nClass Ⅱa\n胃癌：\nClass Ⅱa\n结直肠癌辅助化疗：Class Ⅱa\n胆道恶性肿瘤：\nClass Ⅱa\n淋巴瘤：\nClass Ⅱa","食管癌：\nClass Ⅱb\n胃癌：\nClass Ⅱa\n结直肠癌辅助化疗：Class Ⅱb\n胆道恶性肿瘤：\nClass Ⅱb\n淋巴瘤：\nClass Ⅱb","食管癌：\nCategory B\n胃癌：\nCategory B\n结直肠癌辅助化疗：Category B\n胆道恶性肿瘤：Category B\n淋巴瘤：\nCategory B"]
[23,"巴利昔单抗","粉针","20mg","肝移植抗排斥反应的预防",{"$nulls":4},"20mg iv，术前2h及术后第四天","1.美国FDA未批准巴利昔单抗用于预防成人肝移植排斥反应\n2.2015欧洲肝脏研究学会临床实践指南：肝移植\n3.2018ALTN临床指南：肝移植中的免疫抑制","Class Ⅱa","Class IIb","Category B"]
[24,"贝伐珠单抗","注射液","①100mg:4ml\n②400mg:16ml","继发于年龄相关性黄斑变性的脉络膜新生血管化",{"$nulls":4},"玻璃体内注射1.25mg/0.05ml","1.美国FDA未批准贝伐珠单抗用于治疗继发于年龄相关性黄斑变性的脉络膜新生血管化\n2.《2015美国眼科学会临床指南：年龄相关性黄斑变性（更新版）》\n3.2018英国国家卫生与临床优化研究所NICE指南：年龄相关性黄斑变性（NG.82）","Class Ⅱa","Class Ⅱb","Category B"]
[25,"贝伐珠单抗","注射液\n","①100mg:4ml\n②400mg:16ml\n","转移性肾癌 ",{"$nulls":4},"双周方案：10mg/kg；\n三周方案：7.5mg/kg；              ","1.美国FDA已批准贝伐珠单抗用于治疗转移性肾癌\n2.2016美国肿瘤免疫治疗学会共识声明：免疫疗法治疗肾细胞癌\n3.2018国际老年肿瘤学会意见书：老年转移性肾细胞癌患者的管理\n4.NCCN临床实践指南：肾癌（2019V4）","Class Ⅱb","Class Ⅱb","Category B"]
[26,"贝伐珠单抗","注射液","①100mg:4ml\n②400mg:16ml","转移性乳腺癌",{"$nulls":4},"联合紫杉醇化疗方案时静脉注射的推荐剂量：10 mg/kg，每2周给药1次。 ","1.美国FDA未批准贝伐珠单抗作为联合药物治疗成人转移性乳腺癌\n2.NCCN临床实践指南：乳腺癌（2019.V1）","Class Ⅱa","Class Ⅱb","Category B"]
[27,"贝伐珠单抗","注射液","①100mg:4ml\n②400mg:16ml\n","铂耐药型复发卵巢癌",{"$nulls":4},"1.静脉输注，10mg/kg ，每两周给药一次。联合紫杉醇、多柔比星脂质体或托泊替康（每周给药一次）中的任意一种；                       2.静脉输注，15mg/kg，每3周给药一次。联合托泊替康（每3周给药一次）            ","1.美国FDA已批准贝伐珠单抗联合紫杉醇、多柔比星脂质体或托泊替康中的任意一种用于治疗成人之前接受过不超过2期化疗的铂耐药型复发卵巢癌、输卵管癌或原发性腹膜癌\n2.NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌 （2019.V1）","Class Ⅱa","ClassⅡa","Category B"]
[28,"贝伐珠单抗","注射液","①100mg:4ml\n②400mg:16ml","复发或转移性宫颈癌",{"$nulls":4},"15mg/kg，静脉输注，每3周给药1次。联合紫杉醇和顺铂或紫杉醇和托泊替康中的任意一种","1.美国FDA已批准贝伐珠单抗联合紫杉醇和顺铂或联合紫杉醇和托泊替康用于治疗成人持久性、复发或转移性宫颈癌\n2.NCCN临床实践指南：宫颈癌（2019 V3）                                                                                       ","Class I","Class Ⅱa","Category B"]
[29,"贝伐珠单抗","注射液","0.1g","卵巢上皮癌",{"$nulls":4},"7.5mg/kg，iv，三周为一疗程[2]","1.美国FDA已批准贝伐珠单抗用于治疗成人卵巢上皮癌                \n2.NCCN临床实践指南：卵巢癌2018.v2 ","Class IIa","Class IIb","Category B"]
[30,"贝伐珠单抗","注射液","100mg(4ml)/瓶","1.晚期及复发子宫肿瘤一线联合紫杉醇+顺铂/卡铂\n2.既往接受过化疗且进展的子宫肿瘤二线单药治疗",{"$nulls":4},"15mg/kg q21d                   \n","1.美国FDA已经批准贝伐珠单抗用于复发性子宫肿瘤\n2.NCCN临床实践指南：子宫肿瘤（2019.V４）","micromedex未收录"]
[31,"贝米肝素钠","注射液","2500IU\n3500IU","预防静脉血栓栓塞风险的发生","\n",null,"皮下注射",null,"2500-3500IU","1.英国与西班牙说明书已批准贝米肝素钠注射液用于预防静脉血栓栓塞风险的发生\n2.NICE指南：Venous thromboembolism in over 16s\nReducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism.\n3.Venous thromboembolism in over 16s Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism","micromedex未收录"]
[32,"吡格列酮","片剂","30mg","预防糖尿病心血管系统疾病",{"$nulls":4},"30-45mg qd","1.美国FDA未批准吡格列酮用于预防成人糖尿病心血管系统疾病\n2.2014中国成人2型糖尿病预防的专家共识","Class Ⅱa","Class Ⅱb","Category B"]
[33,"丙酸氟替卡松","乳膏","15g/支",null,null,"3-12月儿童",null,null,"适量外用 每晚1次；疗程不超过1个月","1.FDA说明书已批注丙酸氟替卡松可谨慎使用于3月龄以上儿童；\n2.中国特应性皮炎诊疗指南（2014版）","Class I","ClassIIb ","CategoryB "]
[34,"泊沙康唑","混悬液","400mg","毛霉菌",{"$nulls":4},"200mg，每日4次","1.美国FDA未批准泊沙康唑用于治疗成人霉菌病          \n2.2015中国医药教育协会/《中华结核和呼吸杂志》编辑委员会/中国药学会抗菌药物超说明书用法专家共识 ","Class Ⅱa","Class Ⅱb","Category B"]
[35,"布洛芬","胶囊","300mg","骨关节炎",{"$nulls":4},"1200-3200mg/日，分3-4次服用\n，一般使用不超过10天","1.美国FDA已批准布洛芬用于治疗成人骨关节炎                             \n2.2017美国临床药师实践指南：骨关节炎的管理\n3.2018欧洲抗风湿病联盟建议：炎性关节炎和骨关节炎患者疼痛的管理","Class I","Class I","Category B"]
[36,"地塞米松","①片剂\n②注射液","①0.75mg\n②1ml:5mg","预防化疗药物所致呕吐",{"$nulls":4},"根据不用的化疗方案使用不同的剂量，用法用量参考指南","1.美国FDA未批准地塞米松预防成人化疗药物所致呕吐。\n2.NCCN临床实践指南：止呕（2018.V3）                              \n3.《中国肿瘤治疗相关呕吐防治指南2014版》","Class Ⅱa","Class Ⅱa","Category B"]
[37,"地塞米松","注射液","1ml/5mg","用于早产促胎肺成熟",{"$nulls":4},"5-6mg，im，q12h╳4次[1，2]","1.美国FDA未批准该用法\n2.中华医学会妇产科学分会. 早产的临床诊断与治疗指南（2014）. 中华妇产科杂志.2014,49(7):481-484.\n3.中华医学会. 临床诊疗指南:妇产科学分册[M]. 人民卫生出版社, 2007.\n4.ACOG, Practice Bulletin No. 171: Management of Preterm Labor.Obstet Gynecol. 2016 Oct;128(4):e155-64.","micromedex未收录"]
[38,"丁苯酞","胶囊","100mg","非痴呆型血管性认知障碍",null,null," ",null,"200mg tid,连续服用24周","1.美国FDA未批准丁苯酞用于卒中后认知障碍\n2.《中国痴呆与认知障碍诊治指南2015》\n3.中国卒中学会《卒中后认知障碍管理专家共识2017》\n4.Jia J, Wei C, Liang J, et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease. Alzheimers Dement. 2016 12:89-99.","micromedex中未收录"," "," "]
[39,"度洛西汀","胶囊","①30mg\n②60mg","糖尿病周围神经病性疼痛",{"$nulls":4},"度洛西汀60-120mg/d[2]；\n度洛西汀起始剂量为每日30mg，\n一周后调整到每日60mg[3]","1.美国FDA已批准盐酸度洛西汀用于治疗成人糖尿病周围神经病变性疼痛                 \n2.欧洲神经病联盟《2010 NICE 神经病理性疼痛药物治疗指南》\n3.《神经病理性疼痛诊疗专家共识》（2013）","Class Ⅱa","Class Ⅱa","Category A"]
[40,"度洛西汀","胶囊","①30mg\n②60mg","纤维肌痛",{"$nulls":4},"30mg/d维持一周，增量至60mg/d","美国FDA已批准度洛西汀用于治疗成人纤维肌痛","Class Ⅰ","Class Ⅱa","Category A"]
[41,"多柔比星","脂质体注射液","10ml：20mg","复发或转移性乳腺癌一线单药治疗",{"$nulls":4},"50 mg/m2  q28d[2]\n20-30mg/m2 q21d[3]\n","1.美国FDA未批准该药用于晚期乳腺癌\n2.NCCN临床实践指南乳腺癌2019.v1\n3.中国临床肿瘤学会（CSCO）乳腺癌诊疗指南(2019版)","ClassⅡa","ClassⅡb","CategoryB"]
[42,"多柔比星","脂质体注射液","10ml：20mg","复发卵巢癌一线化疗",{"$nulls":4},"1.铂敏感或复发：卡铂+脂质体阿霉素：剂量30mg/㎡ 每4周1次\n2.铂耐药复发：脂质体阿霉素单药：剂量40-50mg/㎡ 每4周1次","1.美国FDA批准用于含铂化疗失败的卵巢癌\n2.NCCN临床实践指南卵巢癌2019.V1推荐\n3.聚乙二醇化脂质体阿霉素治疗卵巢癌的中国专家共识（2018年）","ClassⅡa","ClassⅡb","CategoryB"]
[43,"多西他赛","注射液","①20mg     \n②80mg","小细胞肺癌 ",{"$nulls":4},"单药75mg/m2，静脉输注，静脉输注时间不少于1小时，每21天重复给药 ","1.美国FDA未批准多西他赛用于小细胞肺癌的治疗\n2.NCCN临床实践指南：小细胞肺癌(2019.V1)","Class Ⅱa","Class Ⅱb","Category B"]
[44,"多西他赛","注射液","①20mg     \n②80mg","局部晚期头颈部鳞状细胞癌",{"$nulls":4},"联合顺铂、氟尿嘧啶使用的3周方案中：多西他赛75mg/m2，第一天给药，静脉输注时间不少于1小时","1. 美国FDA已批准多西他赛用于局部晚期头颈部鳞状细胞癌                              \n2.NCCN临床实践指南：头颈部肿瘤(2018.V2.0)","Class Ⅱa","Class Ⅱa","Category B"]
[45,"多西他赛","注射液","①20mg     \n②80mg","宫颈癌（二线治疗）",{"$nulls":4},"单药75mg/m2，静脉输注，静脉输注时间不少于1小时，每21天重复给药 ","1.美国FDA未批准多西他赛用于宫颈癌\n2.NCCN临床实践指南：宫颈癌(2019.V3)","micromedex中未收录"," "," "]
[46,"多西他赛","注射液","①20mg     \n②80mg","食管癌",{"$nulls":4},"单药75mg/m2，静脉输注，静脉输注时间不少于1小时，每21天重复给药 ","1.美国FDA未批准多西他赛用于食管癌                \n2.NCCN临床实践指南：食道癌和胃食管交界处癌(2018.V2)                   \n","Class Ⅱa","Class Ⅱb","Category B"]
[47,"多西他赛","注射液","①20mg     \n②80mg","\n卵巢上皮癌一线化疗联合卡铂",{"$nulls":4},"卵巢癌 60～75mg/m2联合卡铂AUC=5～6，每3周1次[2] ","1.美国FDA未批准多西他赛用于卵巢上皮癌\n2.NCCN临床实践指南：卵巢癌(2018.V2)","Class I","Class Ⅱb","Category B"]
[48,"多西他赛","注射液","①20mg     \n②80mg","晚期胃癌化疗，联合5-氟尿嘧啶和顺铂",{"$nulls":4},"现推荐使用改良版DCF方案，多西他赛剂量为40mg/m240mg/m2静脉滴注 每三周给药一次，联合5-氟尿嘧啶和顺铂[2] ","1.美国FDA已批准多西他赛与顺铂、氟尿嘧啶联合治疗成人晚期胃癌\n2.NCCN临床实践指南：胃癌治疗指南(2019.V1)  \n3.中国临床肿瘤学会（CSCO）《胃癌诊疗指南》（2018.V1)","Class Ⅱa","Class Ⅱb","Category B"]
[49,"多西他赛","注射液","20mg:0.5ml","头颈部鳞癌诱导化疗或晚期一线治疗",{"$nulls":4},"多西他赛75mg /m2","1、美国FDA已批准多西他赛与顺铂、5-氟尿嘧啶联合用于头颈部鳞癌的诱导化疗\n2、NCCN头颈部肿瘤临床实践指南2019 V1","ClassⅡa","Class Ⅱa","Category B"]
[50,"厄贝沙坦 ","片剂","150mg","糖尿病肾病",{"$nulls":4},"每日150 mg，可增加至300mg qd","美国FDA批准用于2型糖尿病且有高血压病史的糖尿病肾病（肌酐升高，24小时尿蛋白>300mg）","Class I","Class Ⅱa","Category A"]
[51,"厄洛替尼","片剂","150mg","转移性非小细胞肺癌一线治疗",{"$nulls":4},"150mg qd，至少在进食前1小时或进食后2小时服用。","1.美国FDA已经批准厄洛替尼用于转移性非小细胞肺癌一线治疗         \n2. NCCN临床实践指南：非小细胞肺癌（2019.V4）\n3.中国临床肿瘤学会（CSCO)《原发性肺癌诊疗指南》（2017.V1）","Class Ⅱa","Class Ⅱa","Category B"]
[52,"厄洛替尼","片剂","150mg","局部晚期，不可切除或转移性的胰腺癌，联合吉西他滨作为一线治疗方案",{"$nulls":4},"100mg，口服，qd，空腹服用（至少在进食前1小时或进食后2小时服用）。持续用药直到疾病进展或出现不能耐受的毒性反应。联合吉西他滨。","1.美国FDA已批准厄洛替尼联合吉西他滨用于成人局部晚期、不可切除或转移性胰腺癌的一线治疗\n2.NCCN临床实践指南：胰腺癌（2019.V2）","Class Ⅱa","Class Ⅱa","Category B"]
[53,"二甲双胍","片剂","500mg","多囊卵巢综合征",{"$nulls":4},"1.5g/d，分3次服用","1.美国FDA未批准盐酸二甲双胍用于治疗成人多囊卵巢综合症\n2.《2013ENDO美国多囊卵巢综合征的诊疗指南》    \n3.中华医学会妇产科学会《临床诊疗指南·妇产科分册》\n4.《2012 ESHER/ASER共识：多囊卵巢综合征（PCOS）对女性健康的影响》","ClassⅡa","ClassⅡb","Category B"]
[54,"二甲双胍","片剂","500mg","糖尿病预防",{"$nulls":4},"参见指南","1.美国FDA未批准二甲双胍用于预防糖尿病\n2.2019年美国ADA指南\n3.中国2型糖尿病防治指南（2017版）\n4.二甲双胍临床应用专家共识（2018版）\n5.中国糖尿病前期临床干预专家共识（2019）","成人：ClassⅡa\n儿童：ClassⅡb","成人：ClassⅡb\n儿童：ClassⅡb","成人：Category B儿童：Category C"]
[55,"伐地那非","片剂","20mg","肺动脉高压",{"$nulls":4},"5mg qd，2周-4周后改为5mg bid","1.美国FDA未批准伐地那非用于肺动脉高压               \n2.《2009欧洲心脏病学会肺动脉高压诊断和治疗指南》\n3.中华医学会心血管科学会《2010年中国肺高血压诊治指南》 ","Class Ⅱa","Class Ⅱb","Category B"]
[56,"氟尿嘧啶","注射液","10ml:0.25g","头颈部鳞癌全身化疗及辅助化疗",{"$nulls":4},"\n按体表面积一日1000mg/m2，连用1-4d,详见NCCN指南","1.美国FDA未批准氟尿嘧啶用于头颈部鳞癌全身化疗及辅助化疗。                                                    2. NCCN临床实践指南：头颈肿瘤指南（2015.V1.0） ","Class Ⅱa","Class Ⅱb","Category B"]
[57,"氟尿嘧啶","注射液","10ml:250mg","鼻咽癌诱导化疗或晚期一线治疗",{"$nulls":4},"参见指南","1、美国FDA未批准5-FU于鼻咽癌                                2、NCCN头颈部肿瘤临床实践指南2019 V1","ClassⅡa","Class Ⅱb","Category B"]
[58,"氟西汀","分散片","20mg","经前焦虑障碍",{"$nulls":4},"20mg/天，连续治疗或间歇性治疗（月经前14天开始连续服用至月经期第一天），最大剂量80mg/天","美国FDA已经批准氟西汀片用于经前焦虑障碍。（仅限于SARAFEM片剂）","Class I","Class Ⅱa","Category B"]
[59,"氟西汀","分散片","20mg","惊恐障碍",{"$nulls":4},"起始剂量10mg/d,维持一周，增加至20mg/d，若病情控制不理想，可继续增加，最大剂量不超过60mg/d","美国FDA已经批准氟西汀用于强惊恐障碍的治疗","Class I","Class Ⅱa","Category B"]
[60,"氟西汀","分散片","20mg","强迫症",null,"7岁以上儿童青少年",null,null,"起始剂量为10mg/d,维持2周，维持剂量:体重较轻的儿童20mg/d-30 mg/d；青少年及体重较重儿童20mg/d-60 mg/d","美国FDA已经批准氟西汀用于7岁以上儿童强迫症的治疗","Class I","Class Ⅱa","Category B"]
[61,"骨化三醇","胶囊","0.25ug","甲状旁腺功能减退症引起的低钙血症",{"$nulls":4},"起始剂量0.25μg/d，维持剂量0.25～2μg/d[1，2]","1.美国FDA已批准骨化三醇用于甲状旁腺功能减退症引起的低钙血症                                              \n2.中华医学会骨质疏松和骨矿盐疾病分会《2006年甲状旁腺功能减退症和假性甲状旁腺功能减退症诊治指南》\n3.2018年《甲状旁腺功能减退症临床诊疗指南》","Class Ⅰ","Class Ⅱa","Category B"]
[62,"环孢素","胶囊","25mg","系统性红斑狼疮",{"$nulls":4},"按体重每日3～\n5mg/kg，分2次口服[2]","1.美国FDA未批准环孢素用于治疗系统性红斑狼疮                                       \n2.中华医学会风湿病学分会《系统性红斑狼疮诊断及治疗指南》                                \n3.英国风湿病学会《2017BSR成人系统性红斑狼疮的管理指南》\n4.中华医学会风湿学分会《临床诊疗指南·风湿病分册》","Class Ⅱa","Class Ⅱb","Category B"]
[63,"环孢素","胶囊","25mg","干燥综合征",{"$nulls":4},"按体重每日2.5～\n5mg/kg，分2次口服[2]","1.美国FDA未批准环孢素用于治疗干燥综合征                                   \n2.中华医学会风湿病学分会《干燥综合征诊断及治疗指南》             \n3.英国风湿病学会《2017BSR成人原发性干燥综合征的管理指南》","Class Ⅱa","Class Ⅱb","Category B"]
[64,"环孢素","胶囊            ","25mg       ","重度溃疡性结肠炎",{"$nulls":4},"按体重每日2～\n4mg/kg，分2次口服[2]","1.美国FDA未批准环孢素用于治疗溃疡性结肠炎                                     \n2.中华医学会消化病学会《炎症性肠病诊断与治疗的共识意见》                                 \n3.欧洲克罗恩病和结肠炎组织《2017ECCO溃疡性结肠炎循证共识》","Class I","Class Ⅱa","Category B"]
[65,"环磷酰胺"," 粉针","200mg","系统性红斑狼疮",null,null," ",null,"0.5-1.0g/m2，每3-4周一次","1.美国FDA未批准环磷酰胺用于治疗系统性红斑狼疮             \n2.中华医学会风湿病学会《系统性红斑狼疮诊断及治疗指南》                                ","Class Ⅱa","Class Ⅱb","Category B"]
[66,"环磷酰胺"," 粉针","200mg","韦格纳肉芽肿",{"$nulls":4},"0.5-1.0g/m2，每3-4周一次","1.美国FDA未批准环磷酰胺用于治疗韦格纳肉芽肿\n2.中华医学会风湿病学会《韦格纳肉芽肿病诊断和治疗指南》","Class Ⅱa","Class Ⅱa","Category B"]
[67,"吉非替尼","片剂","0.25g","EGFR突变者一线抗非小细胞肺癌",null,null," ",null,"250mg qd","1.美国FDA已批准吉非替尼用于EGFR突变者一线抗非小细胞癌\n2.NCCN临床实践指南：非小细胞肺癌2019.V4\n3.3.中国临床肿瘤学会（CSCO)《原发性肺癌诊疗指南》（2018）","Class Ⅱa","Class Ⅱa  ","Category B"]
[68,"吉西他滨","粉针","①1g\n②200mg","非霍奇金淋巴瘤",null,null," ",null,"1g/m2，滴注30min，分别在第1天和第8天给药，三周为一疗程[2] ","1.美国FDA未批准吉西他滨用于治疗非霍奇金淋巴瘤\n2.NCCN临床实践指南：B细胞淋巴瘤2018.v2","Class Ⅱa","Class Ⅱb","Category B"]
[69,"吉西他滨","粉针","①1g\n②200mg","外周T细胞淋巴瘤",{"$nulls":4},"1g/m2，滴注30min，分别在第1天和第8天给药，三周为一疗程[2] ","1.美国FDA未批准吉西他滨用于治疗外周T细胞淋巴瘤  \n2.NCCN临床实践指南：T细胞淋巴瘤2018. v2  ","Class I","Class I","Category B"]
[70,"吉西他滨","粉针","①1g\n②200mg","肉瘤",{"$nulls":4},"参见指南","1.美国FDA未批准吉西他滨用于治疗肉瘤        \n2.NCCN临床实践指南：软组织肉瘤2018.v2                                         \n3.《软组织肉瘤诊治中国专家共识》（2015年版）","ClassⅡa","Class Ⅱb","Category B"]
[71,"吉西他滨","粉针","①1g\n②200mg","子宫颈癌",{"$nulls":4},"1g/m2，滴注30min，分别在第1天和第8天给药，三周为一疗程[2] ","1.美国FDA未批准吉西他滨用于治疗子宫颈癌    \n2.NCCN临床实践指南：宫颈癌2018.v1","ClassⅡa","Class Ⅱa","Category B"]
[72,"吉西他滨","粉针","①1g\n②200mg","晚期卵巢癌，联合卡铂，治疗在以铂类药物为基础的治疗后至少6个月复发的患者",{"$nulls":4},"1000mg/m2静脉滴注30分钟，每周一次，连续二周，随后休息一周，每三周重复一次","1.美国FDA已批准吉西他滨与卡铂联合用于治疗成人晚期卵巢癌，治疗在以铂类药物为基础的治疗后至少6个月复发的患者\n2.NCCN临床实践指南：卵巢癌包括输卵管癌和原发腹膜癌2018.V2","ClassⅡa","ClassⅡa","Category B"]
[73,"吉西他滨","注射液","①1g\n②200mg","不能手术切除或伴有转移的进展期胆管癌",{"$nulls":4},"1.0g/m2 iv  ，每21d重复 ","1.美国FDA未批准吉西他滨用于不能手术切除或伴有转移的进展展期胆管癌的治疗                               \n2.NCCN临床实践指南：肝胆恶性肿瘤指南2016 V1.0","Class Ⅱa","Class Ⅱb","Category B"]
[74,"吉西他滨","粉针\n","①1g\n②200mg","头颈部癌",{"$nulls":4},"参见指南","1.美国FDA未批准吉西他滨用于治疗成人头颈部癌\n2.NCCN临床实践指南：头颈部癌临床实践指南2015.V1                    ","Class Ⅱa","Class Ⅱb","Category B"]
[75,"吉西他滨","粉针","1g","膀胱癌",{"$nulls":4},"参见指南","1.美国FDA未批准该用法\n2.2019.V3 NCCN 临床实践指南：膀胱癌\n3.《膀胱癌诊治规范（2018版）》","ClassⅡa","Class Ⅱb","Category B"]
[76,"甲氨蝶呤","①片剂②注射","\n2.5mg\n","类风湿关节炎",{"$nulls":4},"口服、肌肉注射、关节腔内或静脉注射均有效，每周给药1次，常用剂量为7.5～20mg／周[4]。\n","1.美国FDA已批准甲氨蝶呤用于对一线治疗包括足剂量NSAIDs效果欠佳或不耐受的成人严重类风湿性关节炎\n2.欧洲风湿病联盟《2009年欧洲风湿病联盟关于类风湿关节炎治疗的指南》\n3.中华医学会风湿学分会《临床诊疗指南·风湿病分册》\n4.中华医学会风湿学分会《类风湿关节炎诊断及治疗指南》\n5.广东省药学会《风湿免疫疾病（类风湿性关节炎）超药品说明书用药专家共识》","Class Ⅰ\n","Class Ⅱb\n","Category B\n"]
[77,"甲氨蝶呤","①片剂          ②粉针③注射液","①2.5mg\n②25mg/ml③1g","系统性红斑狼疮",{"$nulls":4},"7.5-15mg/qw，口服、肌肉注射、静脉注射","1.美国FDA未批准甲氨蝶呤用于治疗成人系统性红斑狼疮\n2.中华医学会风湿学分会《临床诊疗指南·风湿病分册》\n3.中华医学会风湿学分会《系统性红斑狼疮诊断及治疗指南》\n4.广东省药学会《风湿免疫疾病（系统性红斑狼疮）超药品说明书用药专家共识》             ","Class Ⅱa","Class Ⅱb","Category B"]
[78,"甲氨蝶呤","注射液","①5mg\n②100mg","异位妊娠",{"$nulls":4},"可采用全身和局部给药，全身用药的常用剂量为按体重一次0.4mg/kg，每日1次，肌注，5日为一疗程，若单次剂量肌注常用1mg/kg或50mg/m2。 ","1.美国FDA未批准甲氨蝶呤用于治疗成人异位妊娠\n2.中华医学会妇产科分会《临床诊疗指南·妇产科学分册》","ClassⅡa","ClassⅡa","Category B"]
[79,"甲羟孕酮","片剂","片剂：0.5mg, 2mg, 4mg, 10mg, 100 mg,  500 mg  注射剂：1ml:150mg","中枢性早熟(Central precocious puberty)",{"$nulls":4},"4-8mg qd","1.美国FDA未批准该用法\n2.中华医学会《临床诊疗指南·内分泌及代谢性疾病手册》将甲羟孕酮用于治疗性早熟。","Class Ⅱb","Class Ⅱb","Category B"]
[80,"静注人免疫球蛋白","注射液","2.5g：50ml","慢性炎性脱髓鞘性多发性神经根神经病（CIDP）","首次用药总负荷剂量：2g/kg,分成2~4天连续输注；维持输液剂量：1g/kg，可一次性输完或分成2剂连续2天输完，每3周重复一次。",{"$nulls":3},"建议首次输注速率为0.01~0.02ml/kg体重/分钟,若无不良反应可逐渐加快，最快为0.08ml/kg体重/分钟。","1.美国FDA已批准静注人免疫球蛋白用于CIDP以改善神经肌肉残疾和损伤及用于维持治疗防止复发。\n2.Perez E E , Orange J S , Bonilla F , et al. Update on the use of immunoglobulin in human disease: A review of evidence[J]. Journal of Allergy and Clinical Immunology, 2017, 139(3):S1-S46.\n3.中国慢性炎性脱髓鞘性多发性神经根神经病诊疗指南(2010)","Class I","Class Ⅱa","Category A"]
[81,"卡铂","注射液","①15ml:150mg\n②10ml:100mg","非小细胞肺癌",{"$nulls":4},"卡铂AUC 6 d1, 每21d重复","1.美国FDA未批准卡铂用于非小细胞肺癌的治疗\n2.NCCN临床实践指南：非小细胞肺癌指南（2019.V4)","Class Ⅱa","Class Ⅱb","Category B"]
[82,"卡铂","注射液","①15ml:150mg\n②10ml:100mg","胸膜间皮瘤",{"$nulls":4},"卡铂AUC 5 d1，每21d重复","1.美国FDA未批准卡铂用于胸膜间皮瘤的治疗                    \n2.NCCN临床实践指南：恶性胸膜间皮瘤指南（2019. v2)","Class Ⅱa","Class Ⅱb","Category B"]
[83,"卡铂","注射液","①15ml:150mg\n②10ml:100mg","转移性乳腺癌",{"$nulls":4},"卡铂按AUC 6 d1,每21-28d重复","1.美国FDA未批准卡铂用于转移性乳腺癌的治疗\n2.NCCN临床实践指南：乳腺癌指南（2019. v1)","Class Ⅱa","Class Ⅱb","Category B"]
[84,"卡托普利 ","片剂","12.5mg","糖尿病肾病",{"$nulls":4},"饭前1小时口服，25mg/次，每天3次","美国FDA批准用于1型糖尿病且有视网膜病变的糖尿病肾病（24小时尿蛋白>500mg）","Class I","Class Ⅱa","Category B"]
[85,"坎地沙坦酯","片剂","8mg","心力衰竭(NYHA II级至iv级，射血分数40%或以下)",{"$nulls":4},"起始剂量为4mg qd,根据患者耐受程度，大约隔两周可剂量加倍，目标剂量为32mg qd","1.美国FDA已批准坎地沙坦酯用于治疗成人心力衰竭\n2.《中华心血管病杂志》2018,46(10)《中国心力衰竭诊断和治疗指南2018》","Class Ⅱa","Class Ⅱb","Category A"]
[86,"克拉屈滨","注射剂","10ML","1、中低危急性髓性白血病的诱导化疗\n2、难治性/复发性急性髓性白血病",{"$nulls":4},"参见指南","1.美国FDA未批准该用法\n2.（2019.V2）NCCN临床实践指南：急性髓性白血病\n","micromedex未收录"]
[87,"喹硫平","片剂","①25mg       \n②100mg       \n③200mg       \n④300mg","与碳酸锂或丙戊酸钠合并使用，双相障碍维持期治疗辅助用药",{"$nulls":4},"维持日剂量为400-800mg/d，分两次服用，最大日剂量为800mg/d。","美国FDA已批准喹硫平用于治疗成人与碳酸锂或丙戊酸钠合并使用，双相障碍维持期治疗辅助用药 ","Class Ⅱa","Class Ⅱa","Category B"]
[88,"喹硫平","片剂","①25mg        \n②100mg       \n③200mg       \n④300mg","双相障碍Ⅰ型躁狂相急性期",null,"10-17岁青少年",null,null,"400-600mg/d，分两次至三次服用；起始剂量为25 mg/d，每日最大增加剂量≤100mg，最高给药剂量为600mg/d。","美国FDA已批准喹硫平用于治疗青少年（10-17岁）双相障碍Ⅰ型躁狂相急性期","Class IIa","Class Ⅱb","Category B"]
[89,"喹硫平","片剂","①25mg       \n②100mg      \n③200mg      \n④300mg","精神分裂症",null,"13-17岁青少年",null,null,"第一天剂量为50mg/d（国外说明书用法）；第二天为100 mg/d；第三天200 mg/d；第四天300 mg/d；第五天400 mg/d；分2-3次给药，推荐剂量400-800mg/d，日剂量最高为800mg/d。","美国FDA已批准喹硫平用于治疗青少年（13-17岁）精神分裂症（非维持期）","Class IIa","Class Ⅱb","Category B"]
[90,"喹硫平","缓释片","①25mg       \n②100mg      \n③200mg      \n④300mg","重症抑郁辅助用药",{"$nulls":4},"第一天晚上剂量为50mg/d，第三天晚上剂量增加为150mg/d，推荐剂量范围150-300mg/d，最大剂量为300 mg/d。","美国FDA已批准喹硫平用于治疗成人重症抑郁辅助用药","Class Ⅱa","Class Ⅱb","Category B"]
[91,"喹硫平","片剂","①25mg     ②100mg    ③200mg    ④300mg","双相障碍抑郁相急性期单一治疗",{"$nulls":4},"第1日：一次50mg，一日一次。第2日，一次100mg，一日一次。第3日，一次200mg，一日一次。第4日，一次300mg，一日一次。药物睡前服用，推荐每日最大剂量300mg/d。","1.美国FDA已批准喹硫平用于成人双相障碍抑郁相急性期单一治疗。\n2.《2018版加拿大抑郁和焦虑治疗网络/国际双相障碍学会双相障碍管理指南》中，喹硫平是双相障碍I型抑郁期的一线治疗选择之一；也是双相障碍II型抑郁期的一线治疗选择。\n3.《中国双相障碍防治指南（第二版）》中，喹硫平是双相障碍I型抑郁发作急性期的首选推荐药物之一（级别A级），也是双相障碍II型抑郁发作急性期的首选推荐药物（级别A级）。","Class Ⅱa","Class Ⅱa","Category B"]
[92,"拉莫三嗪","片剂","①25mg         \n②50mg         \n③100mg ","双相障碍Ⅰ型",{"$nulls":4},"合用丙戊酸的患者：治疗的前2周25mg qod，之后2周25mg/d，第五周50mg/d，第六周增至目标剂量100mg/d。\n不与酶诱导剂及丙戊酸联用的患者：治疗的前2周25mg/d，之后2周50mg/d，第五周100mg/d，第六周增至目标剂量200mg/d。\n与酶诱导剂联用（不加丙戊酸）的患者：治疗的前2周50mg/d，之后2周100mg/d，第五周200mg/d，第六周300mg/d，第七周增至目标剂量400mg/d。剂量≥100mg/d，分两次服用。","美国FDA已经批准拉莫三嗪用于治疗双相障碍I型 ","Class Ⅱa","Class Ⅱa","Category B"]
[93,"来曲唑","片剂","2.5mg","子宫内膜异位症及多囊卵巢综合症的促排卵治疗",{"$nulls":4},"在月经结束3-5天开始使用，剂量为每天2.5-5mg，连用5天","1.美国FDA未批准来曲唑用于成人治疗子宫内膜异位症及多囊卵巢综合症的促排卵\n2.中华医学会《临床诊疗指南·辅助生殖技术与精子库分册》","Class Ⅱa","Class Ⅱb","Category B"]
[94,"雷珠单抗","注射液","10mg","糖尿病性黄斑水肿               ",{"$nulls":4},"玻璃体注射0.3mg，每月一次 ","美国FDA已批准雷珠单抗用于治疗糖尿病性黄斑水肿","Class Ⅱa","Class Ⅱa","Category B"]
[95,"雷珠单抗","注射液","10mg","静脉栓塞引起的黄斑水肿",{"$nulls":4},"玻璃体注射0.5mg，每月一次","美国FDA已批准雷珠单抗用于治疗静脉栓塞引起的黄斑水肿","Class Ⅰ","Class Ⅱa","Category B"]
[96,"雷珠单抗","注射液","10mg","近视性脉络膜新生血管                            ",{"$nulls":4},"玻璃体注射0.5mg，每月一次","美国FDA已批准雷珠单抗用于治疗近视性脉络膜新生血管","Class Ⅱa","Class Ⅱb","Category B"]
[97,"雷珠单抗","注射液","10mg","糖尿病性视网膜病变",{"$nulls":4},"玻璃体注射0.3mg，每月一次 ","美国FDA已批准雷珠单抗用于治疗糖尿病性视网膜病变","Class Ⅱa","Class Ⅱa","Category B"]
[98,"利拉鲁肽","注射液","3mL：18mg","治疗BMI>27 kg/m2 合并至少一项肥胖并发症的患者；或者BMI>30kg/m2的单纯性肥胖患者"," ","成人","皮下注射",null,"起始剂量为每天0.6 mg。至少1周后，剂量应增加至1.2 mg。根据临床应答情况，为了进一步改善治疗效果，每周调整一次剂量，逐渐调整至1.8mg、2.4mg、3.0mg","1. 美国FDA已批准利拉鲁肽用于治疗BMI>27 kg/m2 合并至少一项肥胖并发症的患者（如高血压、2型糖尿病、高血脂）；或者BMI>30kg/m2的单纯性肥胖患者\n2. 美国内分泌学会《2018TES科学声明：肥胖管理科学》\n3. 美国临床内分泌医师学会(AACE)《2018AACE/ACE共识声明：2型糖尿病综合管理方案》","Class Ⅱa ","Class Ⅱb","Category A"]
[99,"利培酮","①片剂\n②口服液","①2mg\n②30mg:30ml","精神分裂症",null,"13岁及以上儿童",null,null,"青少年起始剂量0.5mg/d, 24h后每天可增加0.5或1mg，如耐受可增至目标剂量3mg/d，有效剂量范围为1-6mg/d\n","1.美国FDA已批准利培酮用于13岁及以上儿童精神分裂症的治疗                         \n2.中华医学会精神病学会《精神分裂症防治指南》 ","儿童：Class Ⅱa       ","儿童：Class Ⅱb       ","儿童：Category B  "]
[100,"利培酮","①片剂       ②口服液","①2mg        \n②30ml：30mg","孤独症相关的易激惹症状",null,"5岁以上儿童青少年",null,null,"体重＜20kg，起始剂量为0.25mg/d，至少4天后剂量可增至0.5mg/d，维持此剂量\n至少14d，若疗效不佳可逐渐加量，调整剂量间隔至少为2周，每次增加0.25mg/d。\n体重≥20kg，起始剂量为0.5mg/d，至少4天后剂量可增至1mg/d，维持此剂量至少14d，若疗效不佳可继续调整剂量，每次\n间隔不少于2周，每次增加0.5mg/d。有效剂量范围为0.5-3mg/d，可一日一次给药或将每日剂量均分为两次服用。目前尚无体重＜15kg的儿童患者的剂量数据。","美国FDA已批准利培酮治疗5岁以上儿童青少年孤独症-易激惹型","Class Ⅰ","Class Ⅱa","Category A"]
[101,"利培酮","①片剂       ②口服液","①2mg        \n②30ml：30mg","双相障碍Ⅰ型",null,"10岁以上儿童青少年",null,null,"儿童起始剂量为0.5mg/d，晨起或晚上口服，调整剂量不少于24小时，增加剂量为0.5-1.0mg/d，目标剂量为1-2.5mg/d。有效剂量为1-6mg/d\n","美国FDA已批准利培酮治疗10岁以上儿童青少年双相障碍Ⅰ型","儿童：Class Ⅱa       ","儿童：Class Ⅱb       ","儿童：Category B  "]
[102,"利妥昔单抗","注射液","500mg","慢性移植物抗宿主病      ",{"$nulls":4},"推荐剂量为375mg/m2 BSA","1.美国FDA未批准利妥昔单抗用于慢性移植物抗宿主病                             \n2.血液学标准委员会/英国血液与骨髓移植学会《2012 BCSH/BSBMT指南:慢性移植物抗宿主病的诊断和管理》                               ","Class Ⅱa","Class Ⅱb","Category B"]
[103,"利妥昔单抗","注射液","①10ml:100mg\n②50ml:500mg","血栓性血小板减少性紫癜",{"$nulls":4},"每周375mg/m2，共治疗4周     ","1.美国FDA未批准利妥昔单抗治疗成人血栓性血小板减少性紫癜                                        \n2.中华医学会血液学分会《 血栓性血小板减少性紫癜诊断与治疗中国专家共识（2012年版）》","Class Ⅱa","Class Ⅱb","Category B"]
[104,"利妥昔单抗","注射液\n","①10ml:100mg\n②50ml:500mg\n","慢性淋巴细胞性白血病，联合氟达拉滨和环磷酰胺",{"$nulls":4},"在开始FC化疗的前1天予静脉输注375mg/m2，在第2-6个化疗疗程（每28天为一疗程）的第1天予静脉输注500mg/m2。减量的FCR方案参考指南[2]","1.美国FDA已批准利妥昔单抗联合氟达拉滨和环磷酰胺用于治疗成人既往未经治疗的和既往经治疗的CD20阳性慢性淋巴细胞白血病\n2.中国慢性淋巴细胞白血病的诊断与治疗指南(2011年版)","Class Ⅱa","Class Ⅱa","Category B"]
[105,"利妥昔单抗","注射液","①10ml:100mg\n②50ml:500mg","难治性重症系统性红斑狼疮",{"$nulls":4},"375mg/m2，qw，共4周;或1000mg，2周后重复1次","1.美国FDA未批准利妥昔单抗用于治疗不能耐受免疫抑制剂治疗或治疗效果欠佳的成人系统性红斑狼疮\n2.中华医学会风湿病学会《系统性红斑狼疮诊断及治疗指南》\n3.广东省药学会《风湿免疫疾病（系统性红斑狼疮）超说明书用药专家共识》","Class Ⅱb\n   ","Class Ⅱb\n","Category B\n"]
[106,"利妥昔单抗","注射液","①10ml:100mg\n②50ml:500mg","类风湿关节炎",{"$nulls":4},"第一疗程予静脉输注500-1000mg/次，0周和2 周各1次；根据病情可在6-12 个月后接受第二个疗程。","1.美国FDA已批准利妥昔单抗用于治疗对一种或多种TNF拮抗剂疗效欠佳的成人中重度类风湿性关节炎,需与MTX联合治疗\n2.中华医学会风湿学分会《类风湿关节炎诊断及治疗指南》\n3.广东省药学会《风湿免疫疾病（类风湿性关节炎）超说明书用药专家共识》","Class Ⅱa","Class Ⅱb","Category B"]
[107,"利妥昔单抗","注射液","①10ml:100mg\n②50ml:500mg","韦格纳肉芽肿",{"$nulls":4},"375mg/m2 qw，共治疗4周","1.美国FDA已批准利妥昔单抗与糖皮质激素联合用于治疗成人韦格纳肉芽肿                  \n2.中华医学会风湿学分会《韦格纳肉芽肿诊断及治疗指南》","Class Ⅱa","Class Ⅱb","Category B"]
[108,"利妥昔单抗","注射液","①10ml:100mg\n②50ml:500mg","显微镜下多血管炎",{"$nulls":4},"375mg/m2 qw，共治疗4周","1.美国FDA已批准与糖皮质激素联合用于治疗成人显微镜下多血管炎\n2.中华医学会风湿病学分会《显微镜下多血管炎诊断及治疗指南》2011","Class Ⅱa","Class Ⅱb","Category B"]
[109,"硫代硫酸钠","针剂","320mg\n640mg","作为非特异性抗炎药，用于皮炎、湿疹、荨麻疹、药物性皮炎，副银屑病的治疗。",{"$nulls":4},"临用前，用灭菌注射用水溶解成5%溶液后应用。 \n常用量：肌内或静脉注射一次0.5-1g。 ","1.《糖皮质激素类药物临床应用指导原则》2011\n2.中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组《中西医结合系统药物治疗湿疹皮炎类皮肤病专家共识（2015版）》\n3.中华医学会《临床诊疗指南·皮肤病与性病分册》","micromedex中未收录"]
[110,"硫唑嘌呤","片剂","50mg","炎症性肠病",{"$nulls":4},"欧洲共识意见推荐的目标剂量：1.5-2.5mg/（kg·d），至少应用3-6个月\n中国患者剂量：1.0-1.5mg/(kg·d) 亦有效[3]","1.美国FDA未批准硫唑嘌呤治疗成人炎症性肠病\n2.中华医学会《临床诊疗指南·消化系统疾病分册》\n3.中华医学会消化病学分会炎症性肠病学组《炎症性肠病诊断与治疗的共识意见(2018年•北京)》   ","Class Ⅱa ","Class Ⅱb","Category B"]
[111,"硫唑嘌呤","片剂","50mg","大动脉炎",{"$nulls":4},"每日口服2mg/kg[2]","1.美国FDA未批准硫唑嘌呤用于治疗大动脉炎                               \n2.中华医学会风湿病学分会《大动脉炎诊断及治疗指南》2011","Class Ⅱa","Class Ⅱb","Category B"]
[112,"柳氮磺吡啶","肠溶片","0.25g/片","强直性脊柱炎",{"$nulls":4},"1-2g/d，分2次口服","1、美国FDA未批准柳氮磺吡啶用于强直性脊柱炎\n2、风湿免疫疾病超药品说明书用药专家共识（之三）--强直性脊柱炎（广东省药学会2016年12月12日印发）\n3、强直性脊柱炎诊断及治疗指南 中华医学会风湿病学分会 2010. 14(8), 557-559","ClassⅡb","ClassⅡb","Category B"]
[113,"罗格列酮","片剂","4mg","糖尿病预防",{"$nulls":4},"4-8mg/d","1.美国FDA未批准罗格列酮用于糖尿病预防\n2.中华医学会内分泌学分会《中国成人2型糖尿病预防的专家共识》2014","Class Ⅱa","Class Ⅱb","Category B"]
[114,"螺内酯","片剂"," 20mg       ","痤疮",{"$nulls":4},"50-200mg","1.美国FDA未批准螺内酯用于治疗成人寻常痤疮\n2.中华医学会《临床诊疗指南•皮肤病与性病分册》 ","Class Ⅱa","Class Ⅱb","Category B"]
[115,"螺内酯","①片剂    \n②胶囊","①4mg        \n②12mg            \n③20mg        ","多囊卵巢综合征所致多毛症 "," ",{"$nulls":3},"50～100mg/d [3] ","1.美国FDA未批准用于多囊卵巢综合征所致多毛症                                        \n2.2018美国内分泌学会临床实践指南《绝经前女性多毛症的评估与治疗》\n3.中华医学会《临床诊疗指南·妇产科学分册》","Class Ⅱa","Class Ⅱb","Category B"]
[116,"氯氮平","片剂","25mg","难治性精神分裂症和复发性自杀行为的精神分裂症","最大日剂量900mg[1]",{"$nulls":3},"FDA剂量：起始剂量12.5mg,qd-bid，滴定剂量：在耐受范围内，每日剂量增加25 - 50mg，两周后达到每日300 - 450 mg的目标剂量;随后的增加应不超过1至2次，每周增加不超过100毫克。","1.美国FDA已批准氯氮平用于治疗难治性精神分裂症和复发性自杀行为的精神分裂症的最大日剂量为900mg\n2.中华医学会《精神分裂症防治指南》,北京大学医学出版社,舒良主编\n3.美国FDA仅批准氯氮平用于难治性精神分裂症和复发性自杀行为的精神分裂症的治疗，鉴于氯氮平大剂量使用时不良反应较多且严重，临床上用于上述适应症时建议重点参考说明书最高剂量","难治性精神分裂：Class Ⅱa；复发性自杀行为的精神分裂：Class Ⅱa","难治性精神分裂：Class Ⅱa；复发性自杀行为的精神分裂症：Class Ⅱb","难治性精神分裂：Category B；复发性自杀行为的精神分裂症：Category B"]
[117,"氯沙坦钾","薄膜衣片","①50mg\n②100mg","糖尿病肾病",{"$nulls":4},"起始剂量50mg/d，根据血压可增量至100mg/d","1.美国FDA已批准氯沙坦用于治疗成人糖尿病肾病\n2.美国糖尿病学会《2019 ADA 糖尿病医学诊疗标准》\n3. 中华医学会糖尿病学分会《中国2型糖尿病防治指南（2017年版）》","Class I","Class Ⅱa","Category B"]
[118,"氯硝西泮","片剂","2mg","惊恐障碍",{"$nulls":4},"起始剂量：0.25mg bid，目标剂量1-4mg/d","美国FDA已经批准氯硝西泮用于治疗成人惊恐障碍 ","Class Ⅰ","Class Ⅱa","Category A"]
[119,"吗替麦考酚酯","片剂","①250mg\n②500mg","肾病综合征",{"$nulls":4},"临床药物治疗学：成人1.5～2.0g/d，分2次服，3-6个月后开始缓慢减量。维持剂量0.5-0.75g/d，维持时间1-2年\n儿童：20～30mg/（kg.d）或800-1200mg/(m2.d)，最大剂量1g，每日两次，治疗时间12-24个月。","1.美国FDA未批准吗替麦考酚酯用于治疗肾病综合征                                                \n2.改善全球肾脏病预后组织《KDIGO肾小球疾病指南》","儿童 Class Ⅱa","儿童 Class Ⅱb","儿童Category B"]
[120,"吗替麦考酚酯","胶囊/片剂","胶囊250mg,片剂500mg","1、用于狼疮性肾炎的诱导缓解及维持治疗；\n2、用于原发性肾小球疾病治疗",{"$nulls":4},"500mg qd","1、美国FDA未批准吗替麦考酚酯用于治疗狼疮性肾炎/用于原发性肾小球疾病治疗\n2、KDIGO肾小球疾病指南《KDIGO Clinical Practice Guideline for Glomerulonephritis》\n3、RCT评价: Dooley MA et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95\n4、自身对照研究: Choi MJ et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 2002 Mar;61(3): 1098-114","（狼疮性肾炎） 成人：Class I       儿童：Class I","（狼疮性肾炎） 成人：Class Ⅱa       儿童：Class Ⅱa","（狼疮性肾炎） 成人：Category A 儿童：Category B"]
[121,"吗替麦考酚酯","胶囊/片剂","0.25g/片\n0． 25 g/粒","治疗系统性红斑狼疮",{"$nulls":4},"1-2g/d，分2次口服","1. 美国FDA未批准吗替麦考酚酯片治疗系统性红斑狼疮。\n2.《关于印发风湿免疫疾病（类风湿关节炎、系统性红斑狼疮）超药品说明书用药专家共识的通知》广东省药学会文件 粤药会（2014）48号 \n3. 2008年EULAR关于SLE治疗推荐对于治疗无反应或激素不能减至较低维持量的SLE患者，MMF是可选用的免疫抑制剂之一","（狼疮性肾炎） 成人：Class I       儿童：Class I","（狼疮性肾炎）      成人：Class Ⅱa       儿童：Class Ⅱa","（狼疮性肾炎）成人：Category A 儿童：Category B"]
[122,"咪喹莫特","乳膏","250mg:12.5mg","基底细胞癌",{"$nulls":4},"外用，睡前涂抹患处，每周五次，持续6周，药物应停留皮肤表面8小时","美国FDA已批准5%的咪喹莫特软膏用于治疗成人浅表的皮肤基底细胞癌 ","Class I","Class Ⅱa","Category B"]
[123,"咪喹莫特","乳膏","250mg:12.5mg","日光性角化病",{"$nulls":4},"外用，睡前涂抹患处，每周两次，持续16周，药物应停留皮肤表面8小时","美国FDA已批准咪喹莫特软膏用于治疗成人日光性角化病","Class I","Class Ⅱa","Category A"]
[124,"米非司酮","片剂","25mg","8-12周流产",{"$nulls":4},"200mg一次性口服；分次服法：米非司酮100mg每天1次口服，连续2d，总量200mg。","1.美国FDA批准米非司酮用于70天内的流产                      \n2.中华医学会计划生育学分会《米非司酮配伍米索前列醇终止8-16周妊娠的应用指南》2015                              ","Class Ⅱa","Class Ⅱb","Category B"]
[125,"米索前列醇","片剂","0.2mg","药物流产;妊娠晚期促宫颈成熟引产",{"$nulls":4},"阴道给药，25ug/次，不可压碎，每日总剂量不超50ug","1.美国FDA未批准米索前列醇用于成人药物流产及促宫颈成熟引产\n2.中华医学会妇产科学分会产科学组《妊娠晚期促子宫颈成熟与引产指南（2014）》","Class IIa","Class IIb","Category B"]
[126,"奈达铂","粉针","10mg","宫颈癌",{"$nulls":4},"每次给药80-100mg/m2，每疗程给药一次，至少停药4周后重复下一个疗程。","1.美国FDA未批准奈达铂用于治疗成人子宫颈癌\n2.日本PDMA已批准奈达铂用于治疗成人子宫颈癌                                         ","micromedex中未收录"]
[127,"帕利哌酮","注射混悬液","①25mg         \n②50mg         \n③75mg         \n④100mg       \n⑤150mg","分裂情感性障碍，单药治疗或者作为情绪稳定剂及抗抑郁药的辅助用药",{"$nulls":4},"治疗首日注射本品150mg，一周后再次注射100mg，前2剂起始治疗药物的注射部位均为三角肌。在首次注射5周后，根据患者的耐受情况和/或疗效，维持剂量可在50-150mg的范围内，每月1次 ","美国FDA已经批准棕榈酸帕利哌酮用于治疗成人广泛性焦虑障碍分裂情感性障碍，单药治疗或者作为情绪稳定剂及抗抑郁药的辅助用药","Class Ⅱa","Class Ⅱb","Category B"]
[128,"帕利哌酮","缓释片","①3mg           \n②6mg          \n③9mg    ","分裂情感性障碍",{"$nulls":4},"起始剂量6mg qd，维持剂量3-12mg/d","美国FDA已经批准帕利哌酮用于治疗成人分裂情感性障碍","Class Ⅱa","Class Ⅱa","Category B"]
[129,"帕利哌酮","缓释片","①3mg           \n②6mg           \n③9mg    ","精神分裂症",null,"12-17岁青少年",null,null,"体重<51kg：起始剂量3mg qd，维持剂量3-6mg/d\n体重>51kg：起始剂量3mg qd，维持剂量3-12mg/d","美国FDA已经批准盐酸帕罗西汀用于治疗12-17岁青少年精神分裂症","Class Ⅱa","Class Ⅱb","Category B"]
[130,"帕利哌酮","缓释片","①3mg           ②6mg           ③9mg    ","双向情感障碍躁狂发作急性期的治疗",{"$nulls":4},"起始剂量6mg/d，可调整至3-12mg/d[1][2]","1.美国FDA未批准帕利哌酮缓释片用于治疗双相情感障碍。\n2.《2018版加拿大抑郁和焦虑治疗网络/国际双相障碍学会双相障碍管理指南》中，帕利哌酮被推荐为躁狂发作急性期的一线治疗选择之一。\n3.《中国双相障碍防治指南（第二版）》中，帕利哌酮是躁狂发作急性期的首选推荐药物之一（级别A级）。","Class Ⅱa","Class Ⅱb","Category B"]
[131,"帕罗西汀","片剂","20mg","广泛性焦虑障碍",{"$nulls":4},"20mg/d","美国FDA已经批准盐酸帕罗西汀用于广泛性焦虑障碍 ","Class I ","Class I","Category B"]
[132,"帕罗西汀","片剂","20mg","创伤后应激障碍",{"$nulls":4},"20mg/d","美国FDA已经批准盐酸帕罗西汀用于创伤后应激障碍","Class I ","Class Ⅱa","Category B"]
[133,"培美曲塞","注射剂 ","200mg/支","复发性卵巢癌",{"$nulls":4},"500mg/m2,每3周一次","1.美国FDA未批准培美曲塞用于成人卵巢癌复发的治疗\n2.NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌（2019.V1）","ClassⅡa","Class Ⅱb","Category B"]
[134,"硼替佐米","注射液","3.5mg","多发性骨髓瘤 ",null,null,"皮下注射",null,"浓度2.5mg/ml ，大腿或腹部轮流注射[1]","1.美国FDA已批准硼替佐米用于多发性骨髓瘤              \n2.NCCN临床实践指南：多发性骨髓瘤2018.v4","Class I ","Class Ⅱa","Category B"]
[135,"硼替佐米","粉针","3.5mg","初治套细胞淋巴瘤",{"$nulls":4},"静脉注射，1.3 mg/m2，3周一个疗程（第1,4,8,11天给药；12-21天停药），共6个疗程","1.美国FDA已批准硼替佐米联合静脉利妥昔单抗、环磷酰胺、阿霉素和口服泼尼松用于治疗成人既往未经治疗的套细胞淋巴瘤\n2.NCCN临床实践指南： 非霍奇金淋巴瘤2018.V2","Class Ⅱa","Class Ⅱa","Category B"]
[136,"泼尼松","片剂","5mg","慢性阻塞性肺疾病（急性加重）",{"$nulls":4},"对需住院治疗的剂型加重期患者可考虑口服泼尼松每日30~40mg，连续5天","1.《2019 GOLD 慢性阻塞性肺疾病全球倡议：COPD诊断、治疗与预防全球策略》                                              2.《临床诊疗指南·呼吸病学分册》(2009版). 人民卫生出版社, 中华医学会","Class Ⅱa","Class Ⅱb","Category B"]
[137,"泼尼松","片剂","5mg","类风湿性关节炎",{"$nulls":4},"起始剂量5-60mg/d,根据个体反应用最小剂量短疗程维持(如<3月)","1.美国 FDA 已批准泼尼松用于治疗RA\n2.风湿免疫疾病(类风湿关节炎) 超药品说明书\n用药专家共识","Class I","Class IIa","Category B"]
[138,"普芦卡必利","片剂","2mg","男性便秘",null,"男性",null,null,"2mg qd","1.欧洲EMA已批准琥珀酸普芦卡必利用于男性便秘                                        2. Dig Dis Sci 2016;61(8):2357-72.        3.Am J Gastroenterol 2015;110(5):741-8.                                           ","micromedex中未收录"]
[139,"普萘洛尔","片剂","10mg","婴幼儿血管瘤",null,"小于一岁",null,null,"5周-5月龄，初始剂量0.6mg/kg qd,间隔至少9小时，分两次口服；一周时，调整为1.1mg/kg qd，分两次口服;维持剂量1.7mg/kg/day，分两次口服，持续6个月。","1.美国FDA已批准普萘洛尔用于治疗儿童（小于1岁）血管瘤\n2.《口服普萘洛尔治疗婴幼儿血管瘤中国专家共识》（2016）","Class Ⅱa","Class Ⅱa","Category A"]
[140,"普瑞巴林","胶囊","75mg","糖尿病周围神经病变—神经病理性疼痛",{"$nulls":4},"起始剂量50mg tid；最大剂量可增至100mg tid（Cr≥60mL/min），但疗程控制在一周内。服用本品300mg/日，2至4周后疼痛未得到充分缓解的患者，如可耐受本品，可增至每次300 mg，每日2次，或每次200mg，每日3次（600mg/日）；肾功能减退患者按照说明书调整剂量","1.美国FDA已批准普瑞巴林用于治疗成人糖尿病周围神经病变                          \n2.欧洲神经病联盟《2010 NICE 神经病理性疼痛药物治疗指南》\n3.《神经病理性疼痛诊疗专家共识》（2013）","Class Ⅱa","Class Ⅱb","Category B"]
[141,"齐拉西酮","胶囊","①20mg         \n②40mg         \n③60mg         \n④80mg","双相障碍Ⅰ型躁狂或混合状态",{"$nulls":4},"起始剂量40mg bid，与餐同服，可根据疗效与耐受性调整为40-80mg bid","美国FDA已批准盐酸齐拉西酮用于治疗成人双相障碍Ⅰ型躁狂或混合状态 ","Class Ⅱa","Class Ⅱa","Category B"]
[142,"齐拉西酮","胶囊","①20mg         \n②40mg         \n③60mg         \n④80mg","与碳酸锂或丙戊酸钠合并使用，双相障碍辅助用药",{"$nulls":4},"40-80mg bid，与锂盐或丙戊酸合用","美国FDA已批准盐酸齐拉西酮用于成人双相障碍的辅助治疗（与锂盐或丙戊酸合用）","Class I ","Class Ⅱb","Category B"]
[143,"去氨加压素","片剂","0.1mg","夜尿症",null,null,"口服",null,"起始安全用量为男性0.1mg，每天1次；女性0.05mg，每天1次，可根据患者的疗效调整剂量。","1、美国FDA批准去氨加压素用于夜尿症\n2、中华泌尿外科杂志《夜尿症临床诊疗中国专家共识》。 \n3、《EAU指南：非神经源性男性下尿路症状（LUTS）包括良性前列腺梗阻（BPO）的管理》推荐夜间多尿情况下使用。","ClassⅡa","ClassⅡa","Category B"]
[144,"沙利度胺","片剂","25mg","系统性红斑狼疮（用于轻型）",{"$nulls":4},"50-100 mg/d","1.美国FDA未批准沙利度胺用于治疗成人红斑狼疮\n2.中华医学会《临床诊疗指南·皮肤病与性病分册》\n3.中华医学会风湿学分会《系统性红斑狼疮诊断及治疗指南》","Class Ⅱa","Class Ⅱb","Category B"]
[145,"沙利度胺","片剂","25mg ","白塞病",{"$nulls":4},"每次25-50mg，每日3次","1.美国FDA未批准沙利度胺用于治疗白塞病\n2.中华医学会风湿学分会《白塞病诊断与治疗指南》","Class Ⅱa","Class Ⅱb","Category B"]
[146,"沙利度胺","片剂","25mg","多发性骨髓瘤",null," ",null,null,"一次25～50mg，每日100-200mg \n","1.美国FDA已批准沙利度胺与地塞米松联合治疗新诊断的成人多发性骨髓瘤                             \n2.NCCN临床实践指南：多发性骨髓瘤临床实践指南（2019.V2）                    \n3.中国医师协会血液科医师分会、中华医学会血液学分会、中国医师协会多发性骨髓瘤专业委员会\n《中国多发性骨髓瘤诊治指南（2017年修订）》","Class Ⅱa","Class Ⅱb","Category B"]
[147,"沙利度胺","片剂","25mg","新诊断的多发性骨髓瘤，与地塞米松联合",{"$nulls":4},"200mg/d，睡前或晚餐后1h，与地塞米松联合治疗28天，为一疗程。地塞米松剂量为40mg/d，分别在第1-4,9-12, 17-20天服用。","1.美国FDA已批准沙利度胺与地塞米松联合治疗新诊断的成人多发性骨髓瘤                             \n2.NCCN临床实践指南：多发性骨髓瘤临床实践指南2019.V2                 \n3.中国医师协会血液科医师分会、中华医学会血液学分会、中国医师协会多发性骨髓瘤专业委员会《中国多发性骨髓瘤诊治指南（2017年修订）》\n4.《内科学》（第九版）,人民卫生出版社,葛均波、徐永健、王辰主编","Class I","Class Ⅱa","Category B"]
[148,"沙利度胺","片剂","25mg/片","强直性脊柱炎",{"$nulls":4},"建议初始剂量25-50mg/d，逐渐增加至有效、可耐受的最低剂量维持，常用量50-100mg/d","1、美国FDA未批准沙利度胺用于强直性脊柱炎\n2、风湿免疫疾病超药品说明书用药专家共识（之三）--强直性脊柱炎（广东省药学会2016年12月12日印发）\n3、强直性脊柱炎诊断及治疗指南 中华医学会风湿病学分会 2010. 14(8), 557-559","ClassⅡa","ClassⅡb","Category C"]
[149,"舍曲林","片剂","50mg","强迫症"," ","6岁或以上",null,null,"6-12岁起始剂量应为25 mg，每日一次；13-17岁起始剂量应为50 mg，每日一次。可根据疗效和耐受性增加剂量，每周调整一次，最大剂量200mg/d","1.美国FDA已批准舍曲林用于6岁以上儿童强迫症           \n2.美国精神病学会APA《Practice guideline for the  Treatment of Patients With Obsessive～Compulsive Disorder》2007","Class I","Class Ⅱa","Category B"]
[150,"舍曲林","片剂","50mg","创伤后应激障碍",{"$nulls":4},"起始剂量为25mg qd，早上或晚上服用，服用一周；一周后，剂量增加至50mg/d，此后剂量调整时间间隔不应短于一周。最大剂量200mg/d。","美国FDA已批准舍曲林用于治疗成人创伤后应激障碍","Class I ","Class I","Category B"]
[151,"舍曲林","片剂","50mg","经前焦虑症",{"$nulls":4},"连续给药：起始剂量50mg qd，在整个月经期的早上或晚上服用。若疗效不佳，剂量可每个月经周期增加50mg/d，直至最大剂量为150mg/d\n黄体期给药：起始剂量50mg qd，在整个黄体期的早上或晚上给药。若疗效不佳，可在每一个新黄体期的前3天先给予50mg/d，后增加至100mg/d。","美国FDA已批准舍曲林用于治疗成人经前焦虑症","Class I ","Class II a","Category B"]
[152,"舍曲林","片剂","50mg","社交恐怖症",{"$nulls":4},"起始剂量为25mg qd，早上或晚上服用，服用一周。一周后，剂量增加至50mg/d，此后剂量调整时间间隔不应短于一周。最大剂量200mg/d。","美国FDA已批准舍曲林用于治疗成人社交恐怖症","Class I ","Class I","Category B"]
[153,"舍曲林","片剂","50mg","早泄",{"$nulls":4},"25-200mg/天或50mg/性交前4-8小时\nmicro：50mg qd，若8周后效果不佳，可增加至100mg/d","1.美国FDA未批准舍曲林用于早泄\n2.《坎贝尔-沃尔什泌尿外科学》，北京大学医学出版社，郭应禄，周利群主译\n3.2017 EAU指南：勃起功能障碍，早泄，阴茎弯曲和异常勃起","Class Ⅱa","Class Ⅱb","Category B"]
[154,"舍曲林","片剂","50mg","抑郁症",null,"6岁以上儿童",null,null,"50-200mg/d ","美国FDA未批准舍曲林用于儿童抑郁症","儿童Class Ⅱb","儿童Class Ⅱb","儿童Category B"]
[155,"鼠神经生长因子","粉针","18ug ","新生儿以及早产儿缺血缺氧性脑病、周围神经病变"," "," "," ",null,"每次1支，用2ml注射用水溶解后肌肉注射 qd，4周为一疗程","1.美国FDA未批准注射用鼠神经生长因子用于新生儿以及早产儿脑损伤、周围神经病变\n2.中国神经生长因子临床应用专家共识协作组：神经生长因子（恩经复）临床应用专家共识\n3.《中华人民共和国药典临床用药须知》2015年版","micromedex中未收录"," "," "]
[156,"索拉非尼","片剂","0.2g","经伊马替尼和舒尼替尼和瑞戈非尼治疗失败的晚期或转移性胃肠道间质瘤","0.4g/bid",{"$nulls":3},"0.4g/bid","1.美国FDA未批准该用法\n2.NCCN临床实践指南-软组织肉瘤（2019.V2）","Class IIa","Class IIb","Category B"]
[157,"他达拉非","片剂","20mg","肺动脉高压",null,"成人",null,null,"40mg qd po","1.美国FDA已经批准他达拉非用于治疗成人肺动脉高压\n2.《2014 ACCP成人肺动脉高压药物治疗指南》\n3.《2015 ESC/ERS肺动脉高压诊断和治疗指南》                   ","Class Ⅱa","Class Ⅱa","Category B"]
[158,"他克莫司","片剂","0.5mg,1mg,5mg","治疗原发性肾病综合征及狼疮性肾炎",{"$nulls":4},"0.5mg qd","1、美国FDA未批准他克莫司用于治疗肾病综合征/狼疮性肾炎\n2、KDIGO肾小球疾病指南《KDIGO Clinical Practice Guideline for Glomerulonephritis》\n3、RCT评价：Praga M et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007 May;71(9):924-30\n4、RCT评价：Bao H et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008 Oct;19(10):2001-10","肾病综合征Class Ⅱa  ","肾病综合征ClassIIb ","肾病综合征CategoryB"]
[159,"他莫昔芬","片剂","10mg","少精引起的不育症",{"$nulls":4},"10~30mg qd[1]","1.美国FDA未批准该用法\n2.中华医学会男科学分会.2013 中华医学会男科疾病诊治系列-男性不育症诊疗指南.","ClassⅡa","Class Ⅱb","Category B"]
[160,"坦索罗辛","片剂","0.2mg","输尿管结石",{"$nulls":4},"0.4mg,qd","1.美国FDA未批准坦索罗辛用于治疗输尿管结石\n2.中华医学会泌尿外科学分会《中国泌尿外科疾病诊断治疗指南》2014","Class Ⅱa","Class Ⅱb","Category B"]
[161,"特立帕肽","注射液","2.4ml","骨质疏松",null,"男性",null,null,"20μg qd 皮下注射","美国FDA已批准特立帕肽可用于男性骨质疏松","Class Ⅱa","Class Ⅱb","Category B"]
[162,"特利加压素","粉针","1mg:5ml","肝肾综合征","1-2mg/次，12h一次；最大剂量12mg/d",null,"静脉推注或滴注",null,"1～2mg/ 次，12h 一次静脉缓慢推注（至少15min）\n或持续静脉点滴，有治疗应答反应则持续应用5～7d；如果无\n反应，1～2mg/ 次,6h 一次静脉缓慢推注或持续静脉点滴，有\n反应则持续应用5～7d。停药后病情反复，可再重复同样剂\n量。如果无反应，可增加剂量，最大剂量12mg/d","1、法国说明书批准特利加压素用于肝肾综合征\n2、2017中华医学会肝病学分会《肝硬化腹水及相关并发症的诊疗指南》\n3、2018《EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis》（2018欧洲肝病学会失代偿性肝硬化临床诊疗指南）","ClassⅡa","Class Ⅲ","Category B"]
[163,"替比夫定","片剂","600mg","慢性乙型病毒性肝炎，围产期传播预防",null,"孕妇",null,null,"本品治疗慢性乙型肝炎的推荐剂量为600mg，每天一次，口服，餐前或餐后均可，不受进食影响","1.美国FDA未批准替比夫定用于高病毒载量的HBsAg阳性孕妇\n2.《慢性乙型肝炎防治指南(2015更新版)》\n3.美国肝病学会《AASLD Guidelines for Treatment of Chronic Hepatitis B》","Class Ⅱa","Class Ⅱb","Category B"]
[164,"替吉奥","胶囊","20mg\n","胆道癌",{"$nulls":4},"一般情况下，根据体表面积决定成人的首次剂量。\n体表面积（㎡） 首次剂量（按替加氟计）\n＜1.25 每次40mg\n≥1.25-＜1.5 每次50mg\n≥1.5 每次60mg\n用法为每日2次、早晚餐后口服，连续给药28天，休息14天，为一个治疗周期。可根据患者情况增减给药量。每次给药量按40mg、50mg、60mg、75mg四个剂量等级顺序递增或递减。上限为75mg/次，下限为40mg/次。","1.日本PMDA已批准替吉奥用于治疗成人胆道癌\n2.《胆管癌诊断与治疗-外科专家共识》","micromedex\n未收录"," "]
[165,"替莫唑胺","胶囊","50mg","转移性恶性黑色素瘤",{"$nulls":4},"每一疗程28天。每日口服200 mg/㎡，在28天为一治疗周期内连续服用5天。","1.美国FDA未批准替莫唑胺用于治疗成人转移性恶性黑色素瘤\n2.NCCN临床实践指南：黑色素瘤2018.V3","Class Ⅱa","Class Ⅱb","Category B"]
[166,"替莫唑胺","胶囊","50mg*7粒","神经内分泌瘤\n（转移性胃/肠/胰/肺/胸腺神经内分泌瘤）",{"$nulls":4},"200 mg/m2/日，每日1次，共5天，每28天为一个周期","1、美国FDA未批准该用法\n2、NCCN临床实践指南-神经内分泌和肾上腺肿瘤诊疗指南（2019.V1）；\n3、《中国胃肠胰神经内分泌肿瘤专家共识》（2016年版）","micromedex未收录"]
[167,"替莫唑胺","胶囊","50mg*7粒","原发中枢神经系统淋巴瘤",{"$nulls":4},"参见指南","\n1、美国FDA未批准该用法\n2、《NCCN临床实践指南-中枢神经系统肿瘤》（2019.V1）；\n3、卫健委恶性淋巴瘤诊疗规范（2015年版）\n","micromedex未收录"]
[168,"万古霉素","粉针","500mg","难辨梭状芽胞杆菌相关性腹泻",null,null,"口服",null,"成人：125mg,q6h,口服，维持10天        儿童：40 mg/kg/day，口服，分三到四次一天，维持7到10天，最大剂量每日2g","1.美国FDA已批准万古霉素用于治疗成人和儿童难辨梭状芽胞杆菌相关性腹泻(只允许口服）   \n","成人：Class Ⅰ  儿童：Class Ⅰ ","成人：Class Ⅱa  儿童：Class Ⅱa  ","成人：Category B  儿童：Category B "]
[169,"文拉法辛","胶囊","①150mg\n②75mg","成人惊恐障碍，伴有或不伴有广场恐惧症",{"$nulls":4},"37.5 mg/d 维持一周. 一周后可增至75 mg/d，最大剂量225mg/d","美国FDA已经批准文拉法辛用于成人惊恐障碍，伴有或不伴有广场恐惧症","Class I ","Class Ⅱa","Category B"]
[170,"文拉法辛","胶囊","①150mg\n②75mg","成人社交恐惧症",{"$nulls":4}," 75mg/d","1、美国FDA已经批准文拉法辛用于成人社交恐惧症  "," Class I          "," Class Ⅱa        "," Category B "]
[171,"乌司他丁","针剂","10万U","休克（出血性休克、细菌性休克、外伤性休克、烧伤性休克）",{"$nulls":4},"在成人中，100,000个单位溶解在500毫升输液中一次，静脉输注每天1至3次，每次1至2小时，或100,000单位溶解于2毫升输液一次，每天缓慢静脉注射1至3次。可根据年龄，症状适当地增减 。","1.日本说明书：\n2.中国严重脓毒症/脓毒性休克治疗指南（2014）\n3.急性循环衰竭中国急诊临床实践专家共识（2016）","micromedex中未收录"]
[172,"乌司他丁","针剂","10万U","脓毒症",{"$nulls":4},"20万，q12h\n","1.中国严重脓毒症/脓毒性休克治疗指南（2014）\n2.Karnad DR1, Bhadade R, Verma PK et al.Intravenous administration of ulinastatin （humanurinary trypsin inhibitor）in severe sepsis：a multicenter randomized controlled study.Intensive Care Med DO I 10.1007/s00134-014-3278-8","micromedex中未收录"]
[173,"西地那非","片剂","100mg","肺动脉高血压",null,"成人",null,null,"5mg或20mg tid，间隔4-6小时。","1.美国FDA已批准西地那非治疗成人肺动脉高压    \n2.《2010年中国肺高血压诊治指南》"," Class Ⅱa   "," Class Ⅱa    "," Category B   "]
[174,"西酞普兰","片剂","①5mg              \n②20mg ","强迫症",{"$nulls":4},"起始剂量及增加剂量为20mg/d（为减少不良反应部分患者可减半），常用目标剂量为40-60mg/d，常用最大剂量为80-120mg/d。【2】国内说明书抑郁症最大剂量为40mg/d","1.美国FDA未批准用于艾司西酞普兰或西酞普兰用于强迫症                              \n2.美国APA精神病学学会《PRACTICE GUIDELINE FOR THE  Treatment of Patients With Obsessive-Compulsive Disorder》 ","成人：Class Ⅱa  儿童：Class Ⅱa ","成人：Class Ⅱb  儿童：Class Ⅱb   ","成人：Category B  儿童：Category B "]
[175,"西妥昔单抗","注射液","100mg:20ml","局部晚期头颈部鳞状细胞癌，联合放疗",{"$nulls":4},"在开始放疗前的一周，起始予400mg/m2，静脉输注120min（最大输注速度为10mg/min）。随后的放疗期间（6-7周），每周予250mg/m2，qw，静脉输注60min（最大输注速度为10mg/min）。","1.美国FDA已批准西妥昔单抗联合放疗用于成人局部晚期头颈部鳞状细胞癌的初始治疗                                                    \n2.NCCN临床实践指南：头颈部癌临床实践指南2018.V2            ","Class I","Class Ⅱa","Category B"]
[176,"西妥昔单抗","注射液","100mg:20ml","以铂类药物为基础的化疗失败后的复发或转移性头颈部鳞状细胞癌，单药治疗",{"$nulls":4},"单药治疗。起始予400mg/m2，静脉输注120min（最大输注速度为10mg/min）。随后每周予250mg/m2，qw，静脉输注60min（最大输注速度为10mg/min），持续用药直到疾病进展或出现不能耐受的毒性反应。       ","1.美国FDA已批准西妥昔单抗单用于治疗成人以铂类药物为基础的化疗失败后的复发或转移性头颈部鳞状细胞癌                                                           \n2.NCCN临床实践指南：头颈部癌临床实践指南 2018.V2            ","Class Ⅱa","Class Ⅱb","Category B"]
[177,"西妥昔单抗","注射液","100mg:20ml","局部复发或转移性头颈部鳞状细胞癌，联合以铂类药物为基础的化疗和5-FU作为一线治疗方案",{"$nulls":4},"在开始以铂类药物为基础的化疗和5-FU治疗的第1天，起始予400mg/m2，静脉输注120min（最大输注速度为10mg/min）。其后每周予250mg/m2，qw，静脉输注60min（最大输注速度为10mg/min），持续用药直到疾病进展或出现不能耐受的毒性反应。                  ","1.美国FDA已批准西妥昔单抗联合以铂类药物为基础的化疗和5-FU用于成人局部复发或转移性头颈部鳞状细胞癌的一线治疗                                                        \n2.NCCN临床实践指南：头颈部癌临床实践指南2019.V1 ","Class Ⅱb    ","Class Ⅱb","Category B"]
[178,"西妥昔单抗","注射液","100mg:20ml","鼻咽癌",{"$nulls":4},"与卡铂联合治疗。开始以卡铂治疗的第1天，起始予西妥昔单抗400mg/m2，静脉输注120min，其后每周予250mg/m2，静脉输注60min。","1.美国FDA未批准西妥昔单抗用于治疗以铂类药物治疗失败的复发或转移的头颈部鳞状细胞癌，联合治疗\n2.NCCN临床实践指南：头颈部癌临床实践指南2018.V2 \n3.Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-3576.","Class Ⅱa","Class Ⅱb","Category B"]
[179,"硝苯地平","①控释片\n②缓释片","①30mg\n②10mg","妊娠期高血压",null,"孕妇",null,null,"1.控释片30mg,qd\n2.缓释制剂 30-120mg/d[3]\n\n","1.美国FDA未批准硝苯地平控释片、硝苯地平缓释片用于妊娠期高血压\n2.中华医学会妇产科学会《临床诊疗指南-妇产科分册》\n3.美国妇产科医师学会ACOG指南","Class Ⅱa","Class Ⅱb","Category B"]
[180,"硝苯地平","片剂","10mg","早产抑制宫缩",null,null,"口服",null,"首次负荷量30mg口服或10mg舌下含服．20分钟一次，共4次。以后改为每4～6小时10～20mg口服或舌下含服，应用不超过3天。","1、美国FDA未批硝苯地平用于早产抑制宫缩\n2.谢幸,孔北华,段涛.妇产科学[M].第九版.中国：人民卫生出版社,2018:96-97页.3.中华医学会《临床诊疗指南·妇产科分册》\n3.《早产的临床诊断与治疗指南.2014》                          ","Class Ⅱb","Class Ⅲ","Category B"]
[181,"缬沙坦","胶囊","80mg","心力衰竭",{"$nulls":4},"起始剂量为40mg bid，根据耐受程度可增加至80mg或160mg 最大给药日剂量为320mg,需分次服用。","1.美国FDA已批准缬沙坦用于治疗成人心力衰竭\n2.《中华心血管病杂志》2018,46(10)《中国心力衰竭诊断和治疗指南2018》\n3.中华医学会《临床诊疗指南.心血管分册》","Class Ⅰ","Class Ⅱa","Category B"]
[182,"缬沙坦","胶囊剂","①80mg\n②160mg","糖尿病肾病患者降尿蛋白",{"$nulls":4},"1.80mg qd [5]\n2.40mg[7]-160mg[6]\n   ","1.美国FDA未批准缬沙坦用于糖尿病肾病患者降尿蛋白\n2. 2017 美国成人高血压预防，检测，评估和管理指南\n3.2012 KDOQI慢性肾脏病评估和管理临床实践指南\n4.Hollenberg NK et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007 Sep;25(9):1921-6\n5.Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003\n6.Jin H, Zhang HN, Hou XL, et al: Clinical study of double dose of valsartan combined with tacrolimus in treatment of diabetic nephropathy. Eur Rev Med Pharmacol Sci 2016; 20(1):174-179.\n7. Suzuki K, Souda S, Ikarashi T, et al: Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract 2002; 57:179-183.","Class Ⅱa","Class Ⅱb","Category B"]
[183,"美金刚","片剂","10mg","血管性痴呆","10-20mg/d","血管性痴呆患者","口服",null,"第一周的剂量为每日5mg，第二周每日10mg，第三周每日15mg，第四周开始以后服用推荐的维持剂量每日20mg","1. 美国FDA尚未批准美金刚用于治疗血管性痴呆；\n2.2016中国血管性认知障碍诊疗指导规范：NMDA受体拮抗剂美金刚可改善轻中度VaD患者的认知功能障碍；\n3.2项临床研究表明，与安慰剂相比，美金刚可改善轻中度血管性痴呆患者的部分症状评分。（Wilcock G, Mobius HJ, & Stoffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychophamacol 2002; 17:297-305.\nOrgogozo JM, Rigaud AS, & Stoffler A: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33:1834-1839.）","Class Ⅱ a","Class Ⅱ b","Category B"]
[184,"多奈哌齐","片剂","5mg、10mg","血管性痴呆","5-10mg/d","血管性痴呆患者","口服",null,"初始治疗用量一日一次，一次5mg，睡前口服。至少维持一个月（一般4-6周），以评价早期的临床反应，及达到稳态浓度。之后可以将剂量增加到一日一次，一次10mg。","1. 美国FDA尚未批准多奈哌齐用于治疗血管性痴呆；\n2.2016中国血管性认知障碍诊疗指导规范：胆碱酯酶抑制剂可用于治疗轻中度VaD，多奈哌齐及卡巴拉汀对VaD患者的认知功能障碍具有改善作用，并且多奈哌齐(10mg/d)可改善VaD患者的行为症状和日常功能。\n3.2项临床研究表明，与安慰剂相比，多奈哌齐可改善血管性痴呆患者的认知和总体功能。（Black S, Roman GC, Geldmacher DS, et al: Efficacy and tolerability of donepezil in vascular dementia. Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34:2323-2332.\nWilkinson D, Doody R, Helme R, et al: Donepezil in vascular dementia. A randomized, placebo-controlled study. Neurology 2003; 61:479-486.）","Class Ⅱ a","Class Ⅱ b","Category B"]
[185,"伊立替康","注射液","2ml:40mg","广泛期小细胞肺癌",{"$nulls":4},"顺铂60mg/m2 d1，伊立替康60mg/m2 d1、d8、d15，每4周重复；顺铂30mg/m2 d1，联合伊立替康65mg/m2 d1、d8，每3周重复；卡铂AUC 5，联合伊立替康 50mg/m2 d1、d8、d15 每29天重复","1.美国FDA未批准伊立替康用于广泛期小细胞肺癌\n2.NCCN临床实践指南：小细胞肺癌2019.V1","Class Ⅱa","联合卡铂Class Ⅱb；联合顺铂Class Ⅱa","Category B"]
[186,"伊立替康","注射液","40mg","胃癌（二线治疗）",{"$nulls":4},"150-180mg/m2 ivd d1 每14d重复    ","1.美国FDA未批准伊立替康用于胃癌（二线治疗）\n2.NCCN临床实践指南：胃癌2018 V3.0\n2.欧洲肿瘤内科学会《2013 ESMO临床实践指南：胃癌的诊断、治疗与随访》\n3.《日本胃癌治疗指南（2014第4版）》","Class Ⅱa","Class Ⅱb","Category B"]
[187,"依达拉奉","注射液","15mg/10ml","用于肌萎缩性侧索硬化症（ALS）的治疗\n",{"$nulls":4},"参见FDA说明书","1.美国FDA已批准依达拉奉用于成人肌萎缩性侧索硬化症（ALS）的治疗\n2.Writing Group & Edaravone (MCI-186) ALS 19 Study Group: Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16(7):505-512.","Class I","Class Ⅱa","Category A"]
[188,"依维莫司","片剂","①2.5mg\n②5mg","乳腺癌（与依西美坦联合使用，用于治疗绝经后激素受体阳性，Her2阴性，使用来曲唑或阿那曲唑失败的进展性乳腺癌患者）",{"$nulls":4},"10mg每日一次口服给药","1.美国FDA已批准飞尼妥与依西美坦联合使用，用于治疗绝经后激素受体阳性，Her2阴性，使用来曲唑或阿那曲唑失败的进展性乳腺癌患者。\n2.NCCN临床实践指南：乳腺癌2018.V2\n3.《ABC2全球晚期乳腺癌指南》                              \n4.《中国抗癌协会乳腺癌诊治指南与规范》（2017年版）                            ","Class Ⅱa","Class Ⅱb","Category B"]
[189,"异环磷酰胺","注射液","1000mg","神经母细胞瘤    ","   ","  ","  ",null,"1.5g/m2[2]","1.美国FDA未批准注射用异环磷酰胺用于神经母细胞癌                                       \n2.《抗肿瘤药物临床应用指导原则》                         ","Class Ⅱa","Class Ⅱb","Category B"]
[190,"异环磷酰胺","注射液","1000mg","儿童急性淋巴细胞白血病    ",{"$nulls":4},"参见指南","1、美国FDA未批准该用法\n2、儿童急性淋巴细胞白血病诊疗规范（2018年版）","Class Ⅱa","Class Ⅱb","Category B"]
[191,"吲哚美辛","片剂","25mg","预防早产",{"$nulls":4},"25mg，q6h，应用不超过48小时 ","1.美国FDA未批准吲哚美辛用于预防早产                \n2.中华医学会. 临床诊疗指南. 妇产科学分册[M]. 人民卫生出版社, 2007.\n3.美国妇产科医师学会ACOG指南","Class Ⅱa","Class Ⅱb","Category B"]
[192,"英夫利西单抗","粉针","100mg","溃疡性结肠炎",null,"6岁或以上"," ",null,"首次5mg/kg静脉滴注，第0、2、6周及之后每8周给予相同剂量各1次。","1.美国FDA已批准英夫利西单抗用于治疗对常规治疗反应不充分中度至严重活动性溃疡性结肠炎                                       \n2.中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》\n3.中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2018年）》                 ","成人：Class I          儿童：Class Ⅱa","成人：Class Ⅱa 儿童：Class Ⅱb","Category B"]
[193,"英夫利西单抗","粉针","100mg","银屑病关节炎",{"$nulls":4},"首次5mg/kg静脉滴注，第0、2、6周及之后每8周给予相同剂量各1次治疗银屑病关节炎","1.美国FDA已批准英夫利昔单抗用于银屑病关节炎的治疗\n2.英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版                                              \n3.欧洲抗风湿病联盟《EULAR—银屑病关节炎药物治疗管理建议》2011版","Class I","Class Ⅱb","Category B"]
[194,"右丙亚胺","粉针","0.25g","预防蒽环类药物引起的心脏毒性",{"$nulls":4},"1.按剂量比：右丙亚胺：蒽环药物=10-20:1 静脉滴注\n","1.美国FDA未批准右丙亚胺针用于预防蒽环类药物引起的心脏毒性\n2.中国临床肿瘤学会中华医学会血液学分会《2013蒽环类药物心脏毒性防治指南》","成人：Class Ⅱa\n儿童：\nClass Ⅱb","成人：Class Ⅱb\n儿童：\nClass Ⅱb","成人：Category A儿童：Category B"]
[195,"卡巴拉汀","胶囊","3mg","血管性痴呆","3-12mg/d","血管性痴呆患者","口服",null,"起始剂量3mg/日，根据个体差异，至少每隔2周增加药量，以达到最大可耐受剂量，但每日不应超过12mg","1.美国FDA尚未批准卡巴拉汀用于治疗血管性痴呆；\n2.2016中国血管性认知障碍诊疗指导规范：胆碱酯酶抑制剂可用于治疗轻中度VaD，多奈哌齐及卡巴拉汀对VaD患者的认知功能障碍具有改善作用。\n3.1项临床研究表明，在血管性痴呆患者中，卡巴拉汀治疗与执行功能及行为症状的轻度改善相关。（Moretti R, Torre P, Antonello RM, et al: Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 2003; 15:265-272.）","Class Ⅱ a","Class Ⅱ b","Category B"]
[196,"紫杉醇","注射液","5ml:30mg","胃癌",null,null," ",null,"新辅助化疗：50mg/m2，d1，联合卡铂 AUC 2 d1，静脉输注，连续5周[2]  ","1.美国FDA未批准紫杉醇用于胃癌              \n2.NCCN临床实践指南：胃癌治疗指南2019.V1","Class Ⅱa","Class Ⅱb","Category B"]
[197,"紫杉醇","注射液","5ml:30mg","宫颈癌",null,null," ",null,"1.联合顺铂。NCCN指南：135mg/m2紫杉醇和顺铂联用，每三周重复一次\n2.单药治疗。一次170mg/m2，滴注24小时，每3周1次[5]","1.美国FDA未批准紫杉醇用于宫颈癌                \n2.NCCN临床实践指南：宫颈癌2019.V3\n3.NCCN临床实践指南：宫颈癌临床实践指南2018.V1\n4.Moore, D. H . Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study[J]. Journal of Clinical Oncology, 2004, 22(15):3113-3119.\n5.Mcguire W P , Blessing J A , Moore D , et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 1996, 14(3):792-5.","Class Ⅱa","Class Ⅱb","Category B"]
[198,"紫杉醇","注射液","5ml:30mg","鼻咽癌",{"$nulls":4},"参见指南","1、美国FDA未批准该用法\n2、《NCCN临床实践指南-头颈部肿瘤》（2019.V1）\n3、转移性鼻咽癌治疗专家共识（2018年版）","ClassⅡa","Class Ⅱb","Category B"]
[199,"紫杉醇","注射液","5ml:30mg","膀胱癌",{"$nulls":4},"参见指南","1、美国FDA未批准该用法\n2、《NCCN临床实践指南-膀胱癌》（2019.V3）","ClassⅡa","ClassIIb ","Category B "]
[200,"紫杉醇","注射液","5ml:30mg","食道癌",{"$nulls":4},"参见指南","1、美国FDA未批准该用法\n2、《NCCN临床实践指南-食道癌》（2019.V2）\n3、卫健委食管癌诊疗规范（2018年版）","ClassⅡa","ClassIIb ","Category B "]
[201,"紫杉醇（白蛋白结合型）","粉针","100mg","局部晚期或转移性的非小细胞肺癌，联合卡铂作为一线治疗方案",{"$nulls":4},"100mg/m2，静脉输注30分钟，在第1天、第8天和第15天给药，每21天为一疗程。联合卡铂。","1.美国FDA已批准紫杉醇（白蛋白结合型）联合卡铂用于成人不适合手术或放疗的局部晚期或转移性非小细胞肺癌的一线治疗\n2.NCCN临床实践指南：非小细胞肺癌临床实践指南（2019.V4）","Class Ⅱa","Class Ⅱb","Category B"]
[202,"紫杉醇（白蛋白结合型）","粉针","100mg","非小细胞肺癌",{"$nulls":4},"参见FDA说明书","1.美国FDA批准联合卡铂用于治疗局部晚期或转移性非小细胞肺癌的一线治疗； \n2.NCCN临床实践指南：非小细胞肺癌（2019.V2）","Class Ⅱa","Class IIb","Category B"]
[203,"紫杉醇(白蛋白结合型)","粉针","100mg","转移性胰腺癌，联合吉西他滨作为一线治疗方案",{"$nulls":4},"125mg/m2，静脉输注30-40分钟，在第1天、第8天和第15天给药，每28天为一疗程。联合吉西他滨。","1.美国FDA已批准紫杉醇(白蛋白结合型)联合吉西他滨用于成人转移性胰腺癌的一线治疗\n2.NCCN临床实践指南：胰腺癌临床实践指南2019.V2\n3.中华人民共和国国家卫生健康委员会《胰腺癌诊疗规范》（2018）\n4.《临床肿瘤学杂志》2014年4月第19卷第4期《胰腺癌综合诊治中国专家共识（2014年版）》","Class Ⅱa","Class Ⅱa","Category B"]
[204,"紫杉醇（白蛋白结合型）","粉针剂","100mg/瓶","转移性黑色素瘤",{"$nulls":4},"参见指南","1、美国FDA未批准该用法\n2、NCCN临床实践指南-皮肤黑色素瘤》（2019.V2）\n3、卫健委黑色素瘤诊疗规范（2018年版）","micromedex未收录"]
[205,"紫杉醇（白蛋白结合型）","粉针剂","100mg/瓶","铂敏感或铂耐药的复发性卵巢癌",{"$nulls":4},"参见指南","1、美国FDA未批准该用法\n2、NCCN临床实践指南-卵巢癌》（2019.V1）\n3、卫健委卵巢癌诊疗规范（2018年版）","ClassⅡa","ClassⅡb","Category B"]
[206,"紫杉醇（白蛋白结合型）","注射剂","100mg","胰腺癌",{"$nulls":4},"参见指南","1、美国FDA说明书批准该用法；\n2、NCCN临床实践指南-胰腺癌》（2019.V2）\n3、卫健委胰腺癌诊疗规范（2018年版）","ClassⅡa","ClassⅡa","Category B"]
[207,"唑来膦酸","注射液","5mg:100ml","骨质疏松",null,"男性",null,null,"5mg静脉注射，每年一次","1.美国FDA已批准唑来膦酸可用于男性骨质疏松\n2.中华医学会骨质疏松和骨矿盐疾病分会《原发性骨质疏松症诊疗指南 ( 2017)》","Class Ⅱa","Class Ⅱb","Category B"]
[208,"茴三硫","胶囊 ","25mg/粒 ","缓解干燥综合症等疾病引起的口干症 ",{"$nulls":4},"25mg,tid","1.《中华人民共和国药典临床用药须知2010版》\n2.《国家处方集》","micromedex未收录"]
["备注：\n1.FDA说明书可在FDA官网上下载：http://www.fda.gov/；\n2.本目录仅供医疗机构参考，超说明书用药应按正规流程规范管理；\n3.引用本目录内容时请注明出处。"]